BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450-455. [PMID: 10569299 DOI: 10.1016/s0002-9343(99)00271-5] [Cited by in Crossref: 1049] [Cited by in F6Publishing: 1115] [Article Influence: 43.7] [Reference Citation Analysis]
Number Citing Articles
1 Drummer C, Saaoud F, Jhala NC, Cueto R, Sun Y, Xu K, Shao Y, Lu Y, Shen H, Yang L, Zhou Y, Yu J, Wu S, Snyder NW, Hu W, Zhuo J‘, Zhong Y, Jiang X, Wang H, Yang X. Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1113883] [Reference Citation Analysis]
2 Yakovleva SV, Pirogova IY. Relationship between cardiometabolic risk factors and 25(OH)D levels in young men with non-alcoholic fatty liver disease. jour 2023. [DOI: 10.31146/1682-8658-ecg-206-10-50-57] [Reference Citation Analysis]
3 Song W, Yoo SH, Jang J, Baik SJ, Lee BK, Lee HW, Park JS. Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis. Gut Liver 2023;17:130-8. [PMID: 36472070 DOI: 10.5009/gnl220041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 孔 繁. Research Progress of Direct Antiviral Drug Therapy for Hepatitis C in Children. ACM 2023;13:140-144. [DOI: 10.12677/acm.2023.131022] [Reference Citation Analysis]
5 Cheon SY, Song J. Novel insights into non-alcoholic fatty liver disease and dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular impairment, and inflammation. Cell Biosci 2022;12:99. [DOI: 10.1186/s13578-022-00836-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zeng J, Fan JG. From NAFLD to MAFLD: Not just a change in the name. Hepatobiliary Pancreat Dis Int 2022;21:511-3. [PMID: 35613992 DOI: 10.1016/j.hbpd.2022.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Musazadeh V, Faghfouri AH, Kavyani Z, Dehghan P. Synbiotic as an adjunctive agent can be useful in the management of hyperglycemia in adults: An umbrella review and meta-research of meta-analysis studies. Journal of Functional Foods 2022;99:105355. [DOI: 10.1016/j.jff.2022.105355] [Reference Citation Analysis]
8 Songtrai S, Pratchayasakul W, Arunsak B, Chunchai T, Kongkaew A, Chattipakorn N, Chattipakorn SC, Kaewsuwan S. Cyclosorus terminans Extract Ameliorates Insulin Resistance and Non-Alcoholic Fatty Liver Disease (NAFLD) in High-Fat Diet (HFD)-Induced Obese Rats. Nutrients 2022;14. [PMID: 36432581 DOI: 10.3390/nu14224895] [Reference Citation Analysis]
9 Zeina AR, Kopelman Y, Mari A, Ahmad HS, Artul S, Khalaila AS, Taher R, Villannueva FZ, Safadi R, Abu Mouch S, Abu Baker F. Pulmonary embolism risk in hospitalized patients with nonalcoholic fatty liver disease: A case-control study. Medicine (Baltimore) 2022;101:e31710. [PMID: 36397431 DOI: 10.1097/MD.0000000000031710] [Reference Citation Analysis]
10 Houttu V, Bouts J, Vali Y, Daams J, Grefhorst A, Nieuwdorp M, Holleboom AG. Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1032164] [Reference Citation Analysis]
11 Chen B, Tang WHW, Rodriguez M, Corey KE, Sanyal AJ, Kamath PS, Bozkurt B, Virk HUH, Pressman GS, Lazarus JV, El-Serag HB, Krittanawong C. NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity? Semin Liver Dis 2022;42:465-74. [PMID: 36241194 DOI: 10.1055/s-0042-1757712] [Reference Citation Analysis]
12 Klimczak S, Śliwińska A. Epigenetic regulation of inflammation in insulin resistance. Semin Cell Dev Biol 2022:S1084-9521(22)00266-X. [PMID: 36109307 DOI: 10.1016/j.semcdb.2022.09.004] [Reference Citation Analysis]
13 Patel S, Haider A, Alvarez-Guaita A, Bidault G, El-Sayed Moustafa JS, Guiu-Jurado E, Tadross JA, Warner J, Harrison J, Virtue S, Scurria F, Zvetkova I, Blüher M, Small KS, O'Rahilly S, Savage DB. Combined genetic deletion of GDF15 and FGF21 has modest effects on body weight, hepatic steatosis and insulin resistance in high fat fed mice. Mol Metab 2022;:101589. [PMID: 36064109 DOI: 10.1016/j.molmet.2022.101589] [Reference Citation Analysis]
14 Barreto BFDM, Punaro GR, Elias MC, Parise ER. IS HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE >2.5 A DISTINGUISHED CRITERIA FOR METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IDENTIFICATION? Arq Gastroenterol 2022;59:402-407. [DOI: 10.1590/s0004-2803.202203000-72] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Bi Y, Lin HY, Li ML, Zhou J, Sun XL. The Association Between Pancreatic Steatosis and Metabolic Syndrome: A 5-Year Follow-up Study Among a General Chinese Population. Pancreas 2022;51:1000-6. [PMID: 36607946 DOI: 10.1097/MPA.0000000000002138] [Reference Citation Analysis]
16 Yeşilot Ş, Özer MK, Gültekin F, Öncü M, Candan İA, Harun Dağdeviren B, Çiçek E. An experimental study to investigate the impact of Aspirin and Vitamin C therapy on fructose induced hepatic and pancreatic damage. TJHSL 2022. [DOI: 10.56150/tjhsl.1143635] [Reference Citation Analysis]
17 Wang X, Zhao B, Sun H, You H, Qu S. Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease. Front Endocrinol 2022;13:866189. [DOI: 10.3389/fendo.2022.866189] [Reference Citation Analysis]
18 Jaroenlapnopparat A, Suppakitjanusant P, Ponvilawan B, Charoenngam N. Vitamin D-Related Genetic Variations and Nonalcoholic Fatty Liver Disease: A Systematic Review. Int J Mol Sci 2022;23:9122. [PMID: 36012386 DOI: 10.3390/ijms23169122] [Reference Citation Analysis]
19 Baratta F, D'erasmo L, Bini S, Pastori D, Angelico F, Del Ben M, Arca M, Di Costanzo A. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ducheix S, Piccinin E, Peres C, Garcia-Irigoyen O, Bertrand-Michel J, Fouache A, Cariello M, Lobaccaro JM, Guillou H, Sabbà C, Ntambi JM, Moschetta A. Reduction in gut-derived MUFAs via intestinal stearoyl-CoA desaturase 1 deletion drives susceptibility to NAFLD and hepatocarcinoma. Hepatol Commun 2022. [PMID: 35903850 DOI: 10.1002/hep4.2053] [Reference Citation Analysis]
21 Cigrovski Berkovic M, Rezic T, Bilic-Curcic I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? World J Clin Cases 2022; 10(20): 6759-6768 [DOI: 10.12998/wjcc.v10.i20.6759] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Muzurović E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension 2022;79:1319-26. [PMID: 35465684 DOI: 10.1161/HYPERTENSIONAHA.122.17982] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
23 Ciardullo S, Perseghin G. Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Marti-Aguado D, Clemente-Sanchez A, Bataller R. Cigarette smoking and liver diseases. J Hepatol 2022;77:191-205. [PMID: 35131406 DOI: 10.1016/j.jhep.2022.01.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Cruz-Pineda WD, Garibay-Cerdenares OL, Rodríguez-Ruíz HA, Matia-García I, Marino-Ortega LA, Espinoza-Rojo M, Reyes-Castillo Z, Castro-Alarcón N, Castañeda-Saucedo E, Illades-Aguiar B, Parra-Rojas I. Changes in the Expression of Insulin Pathway, Neutrophil Elastase and Alpha 1 Antitrypsin Genes from Leukocytes of Young Individuals with Insulin Resistance. Diabetes Metab Syndr Obes 2022;15:1865-76. [PMID: 35757193 DOI: 10.2147/DMSO.S362881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Sayegh NF, Heraoui GNHA, Younes H, Sayegh LN, Boulos C, Sayegh R. Relation of Dietary Patterns and Nutritional Profile to Hepatic Fibrosis in a Sample of Lebanese Non-Alcoholic Fatty Liver Disease Patients. Nutrients 2022;14:2554. [PMID: 35745284 DOI: 10.3390/nu14122554] [Reference Citation Analysis]
27 Patel S, Haider A, Alvarez-guaita A, Bidault G, El-sayed Moustafa JS, Guiu-jurado E, Tadross JA, Warner J, Harrison J, Virtue S, Scurria F, Zvetkova I, Blüher M, Small KS, O’rahilly S, Savage DB. Endogenous GDF15 and FGF21 additively alleviate hepatic steatosis and insulin resistance in obese mice.. [DOI: 10.1101/2022.06.08.495255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Rojano-Toimil A, Rivera-Esteban J, Manzano-Nuñez R, Bañares J, Martinez Selva D, Gabriel-Medina P, Ferrer R, Pericàs JM, Ciudin A. When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. J Clin Med 2022;11:3286. [PMID: 35743358 DOI: 10.3390/jcm11123286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhang Y, Huang J, Xia S, Yang Y, Dong K. Gender Difference in Liver Enzymes in Newly Defined Subgroups of Diabetes Revealed by a Data-Driven Cluster Analysis. Exp Clin Endocrinol Diabetes 2022. [PMID: 35640638 DOI: 10.1055/a-1799-8173] [Reference Citation Analysis]
30 Barreby E, Chen P, Aouadi M. Macrophage functional diversity in NAFLD — more than inflammation. Nat Rev Endocrinol. [DOI: 10.1038/s41574-022-00675-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
31 Dai L, Xu J, Liu B, Dang Y, Wang R, Zhuang L, Li D, Jiao L, Wang J, Zhang L, Zhong LLD, Zhou W, Ji G. Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach. Front Med 2022. [PMID: 35471471 DOI: 10.1007/s11684-021-0880-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Price J, Ma Y, Adimora A, Fischl M, French AL, Golub ET, Konkle-Parker D, Kuniholm MH, Ofotokun I, Plankey M, Sharma A, Tien PC. Multisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV. BMJ Open 2022;12:e055706. [PMID: 35393310 DOI: 10.1136/bmjopen-2021-055706] [Reference Citation Analysis]
33 Bhandari P, Sapra A, Ajmeri MS, Albers CE, Sapra D. Nonalcoholic Fatty Liver Disease: Could It Be the Next Medical Tsunami? Cureus. [DOI: 10.7759/cureus.23806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Nagatomo A, Inoue N, Konno T, Xu Y, Sakamoto C, Sone M, Shibasaka A, Muraoka O, Ninomiya K, Yoshikawa M, Manse Y, Morikawa T. Ursane-type triterpene oligoglycosides with anti-hepatosteatosis and anti-hyperlipidemic activity from the leaves of Ilex paraguariensis A. St.-Hil. J Nat Med 2022. [PMID: 35292883 DOI: 10.1007/s11418-022-01614-5] [Reference Citation Analysis]
35 Kosmalski M, Ziółkowska S, Czarny P, Szemraj J, Pietras T. The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. J Clin Med 2022;11:1375. [PMID: 35268466 DOI: 10.3390/jcm11051375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Madill-Thomsen KS, Abouljoud M, Bhati C, Ciszek M, Durlik M, Feng S, Foroncewicz B, Francis I, Grąt M, Jurczyk K, Klintmalm G, Krasnodębski M, McCaughan G, Miquel R, Montano-Loza A, Moonka D, Mucha K, Myślak M, Pączek L, Perkowska-Ptasińska A, Piecha G, Reichman T, Sanchez-Fueyo A, Tronina O, Wawrzynowicz-Syczewska M, Więcek A, Zieniewicz K, Halloran PF. The molecular phenotypes of injury, steatohepatitis, and fibrosis in liver transplant biopsies in the INTERLIVER study. Am J Transplant 2022;22:909-26. [PMID: 34780106 DOI: 10.1111/ajt.16890] [Reference Citation Analysis]
37 Zhang Y, Liu X, Zhang H, Wang X. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Endocrinol 2022;13:836455. [DOI: 10.3389/fendo.2022.836455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Han JE, Shin HB, Ahn YH, Cho HJ, Cheong JY, Park B, Kim SS. Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus. Sci Rep 2022;12:2538. [PMID: 35169195 DOI: 10.1038/s41598-022-06205-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Martinou E, Pericleous M, Stefanova I, Kaur V, Angelidi AM. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics (Basel) 2022;12:407. [PMID: 35204498 DOI: 10.3390/diagnostics12020407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
40 Pascale RM, Simile MM, Calvisi DF, Feo CF, Feo F. S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent. Cells 2022;11:409. [PMID: 35159219 DOI: 10.3390/cells11030409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
41 Bergram M, Nasr P, Iredahl F, Kechagias S, Rådholm K, Ekstedt M. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. Scand J Gastroenterol 2022;57:60-9. [PMID: 34618619 DOI: 10.1080/00365521.2021.1984572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Gupta A. Etiopathogenesis of insulin resistance. Understanding Insulin and Insulin Resistance 2022. [DOI: 10.1016/b978-0-12-820234-0.00010-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
44 Wang J, Su Z, Feng Y, Xi R, Liu J, Wang P. Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China. BMC Gastroenterol 2021;21:482. [PMID: 34923965 DOI: 10.1186/s12876-021-02072-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
45 Rafiq S, Jeppesen PB. Vitamin D Deficiency Is Inversely Associated with Homeostatic Model Assessment of Insulin Resistance. Nutrients 2021;13:4358. [PMID: 34959910 DOI: 10.3390/nu13124358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Mertens J, De Block C, Spinhoven M, Driessen A, Francque SM, Kwanten WJ. Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy. Front Pharmacol 2021;12:768576. [PMID: 34759828 DOI: 10.3389/fphar.2021.768576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Kiseleva EV, Demidova TY. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the problem of conjunction and phasing. Obes metabol 2021;18:313-319. [DOI: 10.14341/omet12758] [Reference Citation Analysis]
48 Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology 2021;74:1809-24. [PMID: 33811367 DOI: 10.1002/hep.31843] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 33.0] [Reference Citation Analysis]
49 Koulaouzidis G, Charisopoulou D, Kukla M, Marlicz W, Rydzewska G, Koulaouzidis A, Skonieczna-Żydecka K. Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. Prz Gastroenterol 2021;16:196-206. [PMID: 34584580 DOI: 10.5114/pg.2021.109063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Lee SB, Park BJ, Lee YJ, Jung DH. Early Chronic Kidney Disease (G1-G3a) in Combination with Steatosis as a Predictor of Incident Ischemic Heart Disease: A Longitudinal Study in Non-Diabetic Koreans. Biomedicines 2021;9:1358. [PMID: 34680475 DOI: 10.3390/biomedicines9101358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Korochanskaya NV, Durleshter VM, Bacenko MA. S-ademetionine in the treatment of non-alcoholic fatty liver disease (NAFLD). jour 2021. [DOI: 10.31146/1682-8658-ecg-191-7-68-73] [Reference Citation Analysis]
52 Wen X, Wang S, Taveira TH, Akhlaghi F. Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH). PLoS One 2021;16:e0251665. [PMID: 34525124 DOI: 10.1371/journal.pone.0251665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Tsvetkov VV, Tokin II, Nikitina OE, Lioznov DA. Disorders of lipid metabolism in the liver in patients with chronic viral hepatitis. HERALD of North-Western State Medical University named after I I Mechnikov 2021;13:27-38. [DOI: 10.17816/mechnikov71418] [Reference Citation Analysis]
54 da Silva Rosa SC, Nayak N, Caymo AM, Gordon JW. Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue. Physiol Rep. 2020;8:e14607. [PMID: 33038072 DOI: 10.14814/phy2.14607] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 13.5] [Reference Citation Analysis]
55 Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, Foltran L, Ongaro E, Puglisi F. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells 2021;10:2034. [PMID: 34440803 DOI: 10.3390/cells10082034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
56 Ciardullo S, Cannistraci R, Mazzetti S, Mortara A, Perseghin G. Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population. Front Endocrinol (Lausanne) 2021;12:711484. [PMID: 34381424 DOI: 10.3389/fendo.2021.711484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Zhu Y, Yang H, Deng J, Fan D. Ginsenoside Rg5 Improves Insulin Resistance and Mitochondrial Biogenesis of Liver via Regulation of the Sirt1/PGC-1α Signaling Pathway in db/db Mice. J Agric Food Chem 2021;69:8428-39. [PMID: 34309383 DOI: 10.1021/acs.jafc.1c02476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Abbate M, Montemayor S, Mascaró CM, Casares M, Gómez C, Ugarriza L, Tejada S, Abete I, Zulet MÁ, Sureda A, Martínez JA, Tur JA. Albuminuria Is Associated with Hepatic Iron Load in Patients with Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome. J Clin Med 2021;10:3187. [PMID: 34300354 DOI: 10.3390/jcm10143187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
59 Hirono H, Watanabe K, Hasegawa K, Kohno M, Terai S, Ohkoshi S. Impact of continuous positive airway pressure therapy for nonalcoholic fatty liver disease in patients with obstructive sleep apnea. World J Clin Cases 2021; 9(19): 5112-5125 [PMID: 34307562 DOI: 10.12998/wjcc.v9.i19.5112] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Wei Q, Xu X, Guo L, Li J, Li L. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne) 2021;12:635556. [PMID: 34220701 DOI: 10.3389/fendo.2021.635556] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
61 Dankel SN, Bjørndal B, Lindquist C, Grinna ML, Rossmann CR, Bohov P, Nygård O, Hallström S, Strand E, Berge RK. Hepatic Energy Metabolism Underlying Differential Lipidomic Responses to High-Carbohydrate and High-Fat Diets in Male Wistar Rats. J Nutr 2021:nxab178. [PMID: 34132338 DOI: 10.1093/jn/nxab178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Rafiq S, Jeppesen PB. Insulin Resistance Is Inversely Associated with the Status of Vitamin D in Both Diabetic and Non-Diabetic Populations. Nutrients 2021;13:1742. [PMID: 34063822 DOI: 10.3390/nu13061742] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
63 Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World J Gastroenterol 2021; 27(19): 2281-2298 [PMID: 34040322 DOI: 10.3748/wjg.v27.i19.2281] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Park G, Jung S, Wellen KE, Jang C. The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease. Exp Mol Med 2021;53:809-22. [PMID: 34017059 DOI: 10.1038/s12276-021-00614-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
65 Albhaisi S, Sanyal AJ. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2021;12:665987. [PMID: 34040583 DOI: 10.3389/fendo.2021.665987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
66 Álvarez-Amor L, Sierra AL, Cárdenas A, López-Bermudo L, López-Beas J, Andújar E, Pérez-Alegre M, Gallego-Durán R, Varela LM, Martin-Montalvo A, Berná G, Rojas A, Robles-Frías MJ, Hmadcha A, Romero-Gómez M, Kleemann R, Martín F. Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLr-/-.Leiden mice without attenuation of steatohepatitis. Sci Rep 2021;11:8250. [PMID: 33859314 DOI: 10.1038/s41598-021-87761-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
67 Ali N, Sumon AH, Fariha KA, Asaduzzaman M, Kathak RR, Molla NH, Mou AD, Barman Z, Hasan M, Miah R, Islam F. Assessment of the relationship of serum liver enzymes activity with general and abdominal obesity in an urban Bangladeshi population. Sci Rep 2021;11:6640. [PMID: 33758311 DOI: 10.1038/s41598-021-86216-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
68 Abou Assi R, Abdulbaqi IM, Siok Yee C. The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. Pharmaceuticals (Basel) 2021;14:215. [PMID: 33806527 DOI: 10.3390/ph14030215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
69 Ayonrinde OT. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past. JHEP Rep 2021;3:100261. [PMID: 34036255 DOI: 10.1016/j.jhepr.2021.100261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
70 Wu P, Zhang M, Webster NJG. Alternative RNA Splicing in Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:613213. [PMID: 33716968 DOI: 10.3389/fendo.2021.613213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
71 Ardaiz N, Gomar C, Vasquez M, Tenesaca S, Fernandez-Sendin M, Di Trani CA, Belsué V, Escalada J, Werner U, Tennagels N, Berraondo P. Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice. Front Pharmacol 2020;11:591293. [PMID: 33679386 DOI: 10.3389/fphar.2020.591293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 24.0] [Reference Citation Analysis]
73 Sinha B, Datta D, Ghosal S. Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes. JGH Open 2021;5:219-27. [PMID: 33553659 DOI: 10.1002/jgh3.12473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
74 Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology 2021;73:833-42. [PMID: 32780879 DOI: 10.1002/hep.31518] [Cited by in Crossref: 100] [Cited by in F6Publishing: 97] [Article Influence: 50.0] [Reference Citation Analysis]
75 Yabiku K, Nakamoto K, Tsubakimoto M. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes. J Diabetes Res 2020;2020:1682904. [PMID: 33457424 DOI: 10.1155/2020/1682904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Mishina EE, Mayorov AY, Bogomolov PO, Liusina EO, Bueverov AO. Association of insulin resistance and non-alcoholic fatty liver disease. Diabetes mellitus 2021;23:412-423. [DOI: 10.14341/dm12234] [Reference Citation Analysis]
77 Gantzel RH, Kjær MB, Laursen TL, Kazankov K, George J, Møller HJ, Grønbæk H. Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. Front Med (Lausanne) 2020;7:615599. [PMID: 33490096 DOI: 10.3389/fmed.2020.615599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
78 Adetunji CO, Akram M, Mtewa AG, Jeevanandam J, Egbuna C, Ogodo AC, Gautam AK, Gupta A, Onyekere PF, Tupas GD, Ezzat SM, Pareek S, Tijjani H, Sharif N, Ezhilarasan D, Hassan S, Sagar NA, El Sayed AM, Mehdizadeh M, Keskin M, Peculiar-onyekere CO, Walag AMP, Dhar P, Kayode AA, Mohiudin G, Ahmad K, Kumar S, Zainab R, Khan MK, Farooq MA, Vallecilla-yepez L, Abubakar Y, Olatunde A. Biochemical and pharmacotherapeutic potentials of lycopene in drug discovery. Preparation of Phytopharmaceuticals for the Management of Disorders 2021. [DOI: 10.1016/b978-0-12-820284-5.00015-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
79 Franco I, Bianco A, Mirizzi A, Campanella A, Bonfiglio C, Sorino P, Notarnicola M, Tutino V, Cozzolongo R, Giannuzzi V, Aballay LR, Buongiorno C, Bruno I, Osella AR. Physical Activity and Low Glycemic Index Mediterranean Diet: Main and Modification Effects on NAFLD Score. Results from a Randomized Clinical Trial. Nutrients 2020;13:E66. [PMID: 33379253 DOI: 10.3390/nu13010066] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
80 Andersen G, Plum-Mörschel L, Hockings PD, Morsing A, Palle MS, Svolgaard O, Flint A. Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data. Adv Ther 2020;37:4866-76. [PMID: 33006125 DOI: 10.1007/s12325-020-01503-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
81 Akhtar S, Khan A. Analysis of Metabolic Biomarkers in Non-Alcoholic Fatty Liver Disease (NAFLD); A Comprehensive Review. Adv J Grad Res 2020;9:46-58. [DOI: 10.21467/ajgr.9.1.46-58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Tenen DG, Chai L, Tan JL. Metabolic alterations and vulnerabilities in hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2021;9:1-13. [PMID: 33747521 DOI: 10.1093/gastro/goaa066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
83 Alberti G, Gana JC, Santos JL. Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E3531. [PMID: 33212947 DOI: 10.3390/nu12113531] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Ma L, Li H, Hu J, Zheng J, Zhou J, Botchlett R, Matthews D, Zeng T, Chen L, Xiao X, Athrey G, Threadgill DW, Li Q, Glaser S, Francis H, Meng F, Li Q, Alpini G, Wu C. Indole Alleviates Diet-Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3. Hepatology 2020;72:1191-203. [PMID: 31953865 DOI: 10.1002/hep.31115] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 13.7] [Reference Citation Analysis]
85 Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World J Hepatol 2020; 12(9): 533-557 [PMID: 33033564 DOI: 10.4254/wjh.v12.i9.533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
86 Cunha GM, Guzman G, Correa De Mello LL, Trein B, Spina L, Bussade I, Marques Prata J, Sajoux I, Countinho W. Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients With Obesity. Front Endocrinol (Lausanne) 2020;11:607. [PMID: 33042004 DOI: 10.3389/fendo.2020.00607] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
87 Acierno C, Caturano A, Pafundi PC, Nevola R, Adinolfi LE, Sasso FC. Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
88 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 14.3] [Reference Citation Analysis]
89 Jain R, Özgümüş T, Jensen TM, du Plessis E, Keindl M, Møller CL, Falhammar H, Nyström T, Catrina SB, Jörneskog G, Jessen LE, Forsblom C, Haukka JK, Groop PH, Rossing P, Groop L, Eliasson M, Eliasson B, Brismar K, Al-Majdoub M, Nilsson PM, Taskinen MR, Ferrannini E, Spégel P, Berg TJ, Lyssenko V. Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes. Sci Rep 2020;10:11561. [PMID: 32665614 DOI: 10.1038/s41598-020-68130-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
90 Mitra A. An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Cureus 2020;12:e9065. [PMID: 32782883 DOI: 10.7759/cureus.9065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
91 Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 2020;17:387-8. [PMID: 32461575 DOI: 10.1038/s41575-020-0316-6] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 34.3] [Reference Citation Analysis]
92 Kalinovich A, Dehvari N, Åslund A, van Beek S, Halleskog C, Olsen J, Forsberg E, Zacharewicz E, Schaart G, Rinde M, Sandström A, Berlin R, Östenson CG, Hoeks J, Bengtsson T. Treatment with a β-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity. Diabetologia 2020;63:1603-15. [PMID: 32472192 DOI: 10.1007/s00125-020-05171-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
93 Al-Mrabeh A. Pathogenesis and remission of type 2 diabetes: what has the twin cycle hypothesis taught us? Cardiovasc Endocrinol Metab 2020;9:132-42. [PMID: 33225228 DOI: 10.1097/XCE.0000000000000201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
94 Li CH, Chou YT, Shen WC, Lu FH, Yang YC, Wu JS, Chang CJ. Increased risks of different grades of non-alcoholic fatty liver disease in prediabetic subjects with impaired fasting glucose and glucose tolerance, including the isolated glycosylated hemoglobin levels of 5.7-6.4% in a Chinese population. J Diabetes Investig 2020;11:1336-43. [PMID: 32270583 DOI: 10.1111/jdi.13268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Mey JT, Erickson ML, Axelrod CL, King WT, Flask CA, McCullough AJ, Kirwan JP. β-Hydroxybutyrate is reduced in humans with obesity-related NAFLD and displays a dose-dependent effect on skeletal muscle mitochondrial respiration in vitro. Am J Physiol Endocrinol Metab 2020;319:E187-95. [PMID: 32396388 DOI: 10.1152/ajpendo.00058.2020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
96 Nasr P, Fredrikson M, Ekstedt M, Kechagias S. The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. Liver Int 2020;40:1069-78. [PMID: 32087038 DOI: 10.1111/liv.14414] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
97 Radhakrishnan S, Ke JY, Pellizzon MA. Targeted Nutrient Modifications in Purified Diets Differentially Affect Nonalcoholic Fatty Liver Disease and Metabolic Disease Development in Rodent Models. Curr Dev Nutr 2020;4:nzaa078. [PMID: 32494762 DOI: 10.1093/cdn/nzaa078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
98 Roy S. Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience. Case Rep Med 2020;2020:4287075. [PMID: 32280349 DOI: 10.1155/2020/4287075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
99 Indriawati R. The Hepatoprotective Capacity of Steeping <i>kersen</i> Leaves (<i>Muntingia calabura</i> L.) on Diabetic Rat. Electron J Gen Med 2020;17:em225. [DOI: 10.29333/ejgm/7888] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
100 Majdi A, Aoudjehane L, Ratziu V, Islam T, Afonso MB, Conti F, Mestiri T, Lagouge M, Foufelle F, Ballenghien F, Ledent T, Moldes M, Cadoret A, Fouassier L, Delaunay JL, Aït-Slimane T, Courtois G, Fève B, Scatton O, Prip-Buus C, Rodrigues CMP, Housset C, Gautheron J. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol 2020;72:627-35. [PMID: 31760070 DOI: 10.1016/j.jhep.2019.11.008] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 17.0] [Reference Citation Analysis]
101 Chung S, Shin EJ, Choi HK, Park JH, Hwang JT. Anacardic acid mitigates liver fat accumulation and impaired glucose tolerance in mice fed a high-fat and high-sucrose diet. Food Sci Nutr 2020;8:796-804. [PMID: 32148789 DOI: 10.1002/fsn3.1322] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
102 Wattacheril J. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:141-9. [PMID: 32033760 DOI: 10.1016/j.gtc.2019.10.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
103 Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00112. [PMID: 33102794 DOI: 10.1002/edm2.112] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
104 Meroni M, Dongiovanni P, Longo M, Carli F, Baselli G, Rametta R, Pelusi S, Badiali S, Maggioni M, Gaggini M, Fracanzani AL, Romeo S, Gatti S, Davidson NO, Gastaldelli A, Valenti L. Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine 2020;52:102658. [PMID: 32058943 DOI: 10.1016/j.ebiom.2020.102658] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 13.7] [Reference Citation Analysis]
105 Han K, Kwon O, Park HJ, Jung SY, Yang C, Son CG. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial. Trials 2020;21:128. [PMID: 32005283 DOI: 10.1186/s13063-020-4068-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
106 Mohammadi S, Farajnia S, Shadmand M, Mohseni F, Baghban R. Association of rs780094 polymorphism of glucokinase regulatory protein with non-alcoholic fatty liver disease. BMC Res Notes 2020;13:26. [PMID: 31924263 DOI: 10.1186/s13104-020-4891-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
107 Valenti L, Pelusi S. The Natural History of NAFLD: Environmental vs. Genetic Risk Factors. Non-Alcoholic Fatty Liver Disease 2020. [DOI: 10.1007/978-3-319-95828-6_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
108 Brodosi L, Barbanti FA, Petroni ML, Marchignoli F, Marchesini G. Obesity and NAFLD: Same Problem? Non-Alcoholic Fatty Liver Disease 2020. [DOI: 10.1007/978-3-319-95828-6_1] [Reference Citation Analysis]
109 Chang CY, Whitt K, Liu Z, Caldwell SH. The Liver and Insulin Resistance: The Important Convergence of Endocrinology and Hepatology. Contemporary Endocrinology 2020. [DOI: 10.1007/978-3-030-25057-7_13] [Reference Citation Analysis]
110 Ye FZ, Liu WY, Zheng KI, Pan XY, Ma HL, Wang XD, Chen YP, Zheng MH. Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2020;32:80-6. [PMID: 31625959 DOI: 10.1097/MEG.0000000000001483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
111 Morikawa T, Nagatomo A, Oka T, Miki Y, Taira N, Shibano-Kitahara M, Hori Y, Muraoka O, Ninomiya K. Glucose Tolerance-Improving Activity of Helichrysoside in Mice and Its Structural Requirements for Promoting Glucose and Lipid Metabolism. Int J Mol Sci 2019;20:E6322. [PMID: 31847420 DOI: 10.3390/ijms20246322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Chang TC, Chiang H, Lai YH, Huang YL, Huang HC, Liang YC, Liu HK, Huang C. Helminthostachys zeylanica alleviates hepatic steatosis and insulin resistance in diet-induced obese mice. BMC Complement Altern Med 2019;19:368. [PMID: 31836013 DOI: 10.1186/s12906-019-2782-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
113 Kaplan A, Price JC. HIV-Associated NAFLD: Disease Burden and Management. Curr Hepatology Rep 2019;18:482-91. [DOI: 10.1007/s11901-019-00501-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Inoue MK, Nakatsu Y, Yamamotoya T, Hasei S, Kanamoto M, Naitou M, Matsunaga Y, Sakoda H, Fujishiro M, Ono H, Kushiyama A, Asano T. Pin1 Plays Essential Roles in NASH Development by Modulating Multiple Target Proteins. Cells 2019;8:E1545. [PMID: 31795496 DOI: 10.3390/cells8121545] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
115 Cunha V, Cotrim HP, Rocha R, Carvalho K, Lins-Kusterer L. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Ann Hepatol 2020;19:232-7. [PMID: 31836424 DOI: 10.1016/j.aohep.2019.10.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
116 Akinkugbe AA, Barritt AS, Cai J, Offenbacher S, Thyagarajan B, Khambaty T, Singer R, Kallwitz E, Heiss G, Slade GD. Periodontitis and prevalence of elevated aminotransferases in the Hispanic Community Health Study/Study of Latinos. J Periodontol 2018;89:949-58. [PMID: 29717494 DOI: 10.1002/JPER.17-0579] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
117 Hann M, Zeng Y, Zong L, Sakurai T, Taniguchi Y, Takagaki R, Watanabe H, Mitsuzumi H, Mine Y. Anti-Inflammatory Activity of Isomaltodextrin in a C57BL/6NCrl Mouse Model with Lipopolysaccharide-Induced Low-Grade Chronic Inflammation. Nutrients 2019;11:E2791. [PMID: 31731774 DOI: 10.3390/nu11112791] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
118 Chiang H, Lee JC, Huang HC, Huang H, Liu HK, Huang C. Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice. Br J Pharmacol 2020;177:239-53. [PMID: 31497874 DOI: 10.1111/bph.14859] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
119 Pennisi G, Celsa C, Spatola F, Dallio M, Federico A, Petta S. Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. Int J Environ Res Public Health 2019;16:E4334. [PMID: 31703268 DOI: 10.3390/ijerph16224334] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
120 Hartley A, Santos Ferreira DL, Anderson EL, Lawlor DA. Metabolic profiling of adolescent non-alcoholic fatty liver disease. Wellcome Open Res 2018;3:166. [PMID: 30687796 DOI: 10.12688/wellcomeopenres.14974.2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
121 Hartley A, Santos Ferreira DL, Anderson EL, Lawlor DA. Metabolic profiling of adolescent non-alcoholic fatty liver disease. Wellcome Open Res 2018;3:166. [PMID: 30687796 DOI: 10.12688/wellcomeopenres.14974.2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
122 Arase Y, Shiraishi K, Anzai K, Sato H, Teramura E, Tsuruya K, Hirose S, Deguchi R, Toyoda M, Mine T, Kagawa T. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clin Drug Investig 2019;39:631-41. [PMID: 30993553 DOI: 10.1007/s40261-019-00785-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
123 Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol 2019; 25(33): 4904-4920 [PMID: 31543682 DOI: 10.3748/wjg.v25.i33.4904] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 51] [Article Influence: 12.8] [Reference Citation Analysis]
124 Mishra N, Mishra S. Signal transducer and activator of transcriptions (STATs)-at the crossroads of obesity-linked non-alcoholic steatohepatitis and hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8:407-10. [PMID: 31489316 DOI: 10.21037/hbsn.2019.03.21] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep 2019;1:329-41. [PMID: 32039383 DOI: 10.1016/j.jhepr.2019.08.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 15.5] [Reference Citation Analysis]
126 Corbit KC, Wilson CG, Lowe D, Tran JL, Vera NB, Clasquin M, Mattis AN, Weiss EJ. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma. JCI Insight 2019;5:131310. [PMID: 31393852 DOI: 10.1172/jci.insight.131310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
127 Taliento AE, Dallio M, Federico A, Prati D, Valenti L. Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease. Int J Environ Res Public Health 2019;16:E2755. [PMID: 31375010 DOI: 10.3390/ijerph16152755] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
128 Hajifathalian K, Torabi Sagvand B, McCullough AJ. Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology 2019;70:511-21. [PMID: 30125379 DOI: 10.1002/hep.30226] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 16.0] [Reference Citation Analysis]
129 Layman JI, Pereira DL, Chellan N, Huisamen B, Kotzé SH. A histomorphometric study on the hepatoprotective effects of a green rooibos extract in a diet-induced obese rat model. Acta Histochem 2019;121:646-56. [PMID: 31153588 DOI: 10.1016/j.acthis.2019.05.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
130 Zhu F, Li YM, Feng TT, Wu Y, Zhang HX, Jin GY, Liu JP. Freeze-dried Si-Ni-San powder can ameliorate high fat diet-induced non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(24): 3056-3068 [PMID: 31293341 DOI: 10.3748/wjg.v25.i24.3056] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
131 Corbit KC, Wilson CG, Lowe D, Tran JL, Vera NB, Clasquin M, Mattis AN, Weiss EJ. Adipocyte JAK2 mediates aging-associated metabolic liver disease and progression to hepatocellular carcinoma.. [DOI: 10.1101/681809] [Reference Citation Analysis]
132 Yamauchi A, Kamiyoshi A, Sakurai T, Miyazaki H, Hirano E, Lim HS, Kaku T, Shindo T. Development of a mouse iron overload-induced liver injury model and evaluation of the beneficial effects of placenta extract on iron metabolism. Heliyon 2019;5:e01637. [PMID: 31193082 DOI: 10.1016/j.heliyon.2019.e01637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
133 Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2019;16:377-86. [PMID: 31024089 DOI: 10.1038/s41575-019-0144-8] [Cited by in Crossref: 249] [Cited by in F6Publishing: 238] [Article Influence: 62.3] [Reference Citation Analysis]
134 Hamaguchi M, Hashimoto Y, Obora A, Kojima T, Fukui M. Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study. BMJ Open Gastroenterol 2019;6:e000295. [PMID: 31275587 DOI: 10.1136/bmjgast-2019-000295] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
135 Pastore M, Grimaudo S, Pipitone RM, Lori G, Raggi C, Petta S, Marra F. Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. Front Pharmacol 2019;10:604. [PMID: 31191323 DOI: 10.3389/fphar.2019.00604] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
136 Liao YY, Yeh CK, Huang KC, Tsui PH, Yang KC. Metabolic Characteristics of a Novel Ultrasound Quantitative Diagnostic Index for Nonalcoholic Fatty Liver Disease. Sci Rep 2019;9:7922. [PMID: 31138858 DOI: 10.1038/s41598-019-44453-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
137 Uranga RM, Keller JN. The Complex Interactions Between Obesity, Metabolism and the Brain. Front Neurosci 2019;13:513. [PMID: 31178685 DOI: 10.3389/fnins.2019.00513] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 12.3] [Reference Citation Analysis]
138 Machado TQ, Pereira-silva DC, Gonçalves LF, Fernandes-santos C. Brown Adipose Tissue Remodeling Precedes Cardiometabolic Abnormalities Independent of Overweight in Fructose-Feed Mice.. [DOI: 10.1101/615674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 22.5] [Reference Citation Analysis]
140 Lattuada G, Radaelli MG, De Cobelli F, Esposito A, Manzoni G, Perra S, Del Maschio A, Castoldi G, Perseghin G. Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver. Oxid Med Cell Longev 2019;2019:9796175. [PMID: 31097978 DOI: 10.1155/2019/9796175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
141 Li WD, Xia JR, Lian YS. MiR-15b can target insulin receptor to regulate hepatic insulin signaling in mice. Anim Cells Syst (Seoul) 2019;23:82-9. [PMID: 30949394 DOI: 10.1080/19768354.2019.1583125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
142 Kumar P, Sharma H, Dev K, Rana A, Kumar S. Preclinical Studies of the Lemon Hill as a Multi-approach Antioxidant and Antidiabetic Plant: Citrus Pseudolimon Tanaka. Journal of Herbs, Spices & Medicinal Plants 2019;25:69-87. [DOI: 10.1080/10496475.2019.1570994] [Reference Citation Analysis]
143 Li WD, Xia JR, Lian YS. Hepatic miR‑215 target Rictor and modulation of hepatic insulin signalling in rats. Mol Med Rep 2019;19:3723-31. [PMID: 30896868 DOI: 10.3892/mmr.2019.10031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
144 Jiang M, Wu N, Chen X, Wang W, Chu Y, Liu H, Li W, Chen D, Li X, Xu B. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease. J Int Med Res 2019;47:1453-66. [PMID: 30871397 DOI: 10.1177/0300060519833527] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
145 Liu M, Liu S, Shang M, Liu X, Wang Y, Li Q, Mambiya M, Yang L, Zhang Q, Zhang K, Nie F, Zeng F, Liu W. Association between ADIPOQ G276T and C11377G polymorphisms and the risk of non-alcoholic fatty liver disease: An updated meta-analysis. Mol Genet Genomic Med 2019;7:e624. [PMID: 30838812 DOI: 10.1002/mgg3.624] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
146 Cantoral A, Contreras-Manzano A, Luna-Villa L, Batis C, Roldán-Valadez EA, Ettinger AS, Mercado A, Peterson KE, Téllez-Rojo MM, Rivera JA. Dietary Sources of Fructose and Its Association with Fatty Liver in Mexican Young Adults. Nutrients 2019;11:E522. [PMID: 30823422 DOI: 10.3390/nu11030522] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
147 Abdelmegeed MA, Ha SK, Choi Y, Akbar M, Song BJ. Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances. Curr Mol Pharmacol 2017;10:207-25. [PMID: 26278393 DOI: 10.2174/1874467208666150817111114] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 12.3] [Reference Citation Analysis]
148 Tanash HA, Piitulainen E. Liver disease in adults with severe alpha-1-antitrypsin deficiency. J Gastroenterol 2019;54:541-8. [PMID: 30680526 DOI: 10.1007/s00535-019-01548-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
149 Al Batran R, Gopal K, Aburasayn H, Eshreif A, Almutairi M, Greenwell AA, Campbell SA, Saleme B, Court EA, Eaton F, Light PE, Sutendra G, Ussher JR. The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity. JCI Insight 2019;4:124643. [PMID: 30626749 DOI: 10.1172/jci.insight.124643] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
150 Love-osborne K. Prediabetes and Type 2 Diabetes: An Emerging Epidemic Among Obese Youth. Global Perspectives on Childhood Obesity 2019. [DOI: 10.1016/b978-0-12-812840-4.00004-9] [Reference Citation Analysis]
151 Samji NS, Verma R, Satapathy SK. Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. J Clin Exp Hepatol 2019;9:497-505. [PMID: 31516266 DOI: 10.1016/j.jceh.2019.05.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
152 Younes R, Bugianesi E. The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality. Curr Hepatology Rep 2018;17:336-344. [DOI: 10.1007/s11901-018-0422-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
153 Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? World J Hepatol 2018; 10(11): 790-794 [PMID: 30533179 DOI: 10.4254/wjh.v10.i11.790] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
154 Suceveanu A, Mazilu L, Gheorghe A, Pantea Stoian A, Voinea F, Suceveanu A. Metabolic Risk Factors in Hepatocellular Carcinoma. Liver Cancer 2018. [DOI: 10.5772/intechopen.80527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
155 Sung KT, Kuo R, Sun JY, Hung TC, Chang SC, Liu CC, Yun CH, Wu TH, Hung CL, Yeh HI, Hou CJ, Cury RC, Zidar DA, Bezerra HG, Longenecker CT. Associations between CT-determined visceral fat burden, hepatic steatosis, circulating white blood cell counts and neutrophil-to-lymphocyte ratio. PLoS One. 2018;13:e0207284. [PMID: 30458019 DOI: 10.1371/journal.pone.0207284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
156 Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view. Aliment Pharmacol Ther 2018;48:892-913. [PMID: 30194708 DOI: 10.1111/apt.14952] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
157 Gonçalves NB, Bannitz RF, Silva BR, Becari DD, Poloni C, Gomes PM, Foss MC, Foss-Freitas MC. α-Linolenic acid prevents hepatic steatosis and improves glucose tolerance in mice fed a high-fat diet. Clinics (Sao Paulo) 2018;73:e150. [PMID: 30379219 DOI: 10.6061/clinics/2018/e150] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
158 Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99-128. [PMID: 30343320 DOI: 10.1007/s00018-018-2947-0] [Cited by in Crossref: 202] [Cited by in F6Publishing: 185] [Article Influence: 40.4] [Reference Citation Analysis]
159 Horst AK, Najjar SM, Wagener C, Tiegs G. CEACAM1 in Liver Injury, Metabolic and Immune Regulation. Int J Mol Sci 2018;19:E3110. [PMID: 30314283 DOI: 10.3390/ijms19103110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
160 Ahn HY, Kim HH, Hwang JY, Park C, Cho BY, Park YJ. Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression. PPAR Res 2018;2018:9568269. [PMID: 30363699 DOI: 10.1155/2018/9568269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
161 Khammas ASA, Hassan HA, Salih SQM, Kadir H, Ibrahim RM, Nasir NNM, Mahmud R. Prevalence and risk factors of sonographically detected non alcoholic fatty liver disease in a screening centre in Klang Valley, Malaysia: an observational cross-sectional study. Porto Biomed J 2019;4:e31. [PMID: 31595260 DOI: 10.1016/j.pbj.0000000000000031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
162 Watanabe T, Takeuchi T, Kubota N, Wainai T, Kataoka K, Nakaya T, Sugimoto A, Sato T, Ohira H, Tsujino I, Kumagai K, Kubota T, Hasegawa C, Tokuyama K, Ueki K, Yamauchi T, Mishina M, Kadowaki T. A transgenic mutant mouse line accompanied by the complete deletion of interleukin-33 showed insulin and leptin resistances.. [DOI: 10.1101/416529] [Reference Citation Analysis]
163 Ani PN, Aginam PC. Effect of Citrus maxima juice on fasting blood glucose, lipid profile, liver enzyme and body weight. NFS 2018;48:755-63. [DOI: 10.1108/nfs-01-2018-0002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
164 Dalvi PS, Yang S, Swain N, Kim J, Saha S, Bourdon C, Zhang L, Chami R, Bandsma RHJ. Long-term metabolic effects of malnutrition: Liver steatosis and insulin resistance following early-life protein restriction. PLoS One 2018;13:e0199916. [PMID: 29965973 DOI: 10.1371/journal.pone.0199916] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
165 Howell GE 3rd, McDevitt E, Henein L, Mulligan C, Young D. Alterations in cellular lipid metabolism produce neutral lipid accumulation following exposure to the organochlorine compound trans-nonachlor in rat primary hepatocytes. Environ Toxicol 2018;33:962-71. [PMID: 29964320 DOI: 10.1002/tox.22583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
166 Zaki M, Yousef W, Kamal S, Mohamed R, Saleh O, Ezzat W. Association Between Metabolic Abnormalities and Non-Alcoholic Fatty Liver in Obese Premenopausal Women. Biomed Pharmacol J 2018;11:1161-1166. [DOI: 10.13005/bpj/1477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
167 Wu J, Yao XY, Shi RX, Liu SF, Wang XY. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health. 2018;15:77. [PMID: 29747678 DOI: 10.1186/s12978-018-0519-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 11.6] [Reference Citation Analysis]
168 Enooku K, Kondo M, Fujiwara N, Sasako T, Shibahara J, Kado A, Okushin K, Fujinaga H, Tsutsumi T, Nakagomi R, Minami T, Sato M, Nakagawa H, Kondo Y, Asaoka Y, Tateishi R, Ueki K, Ikeda H, Yoshida H, Moriya K, Yotsuyanagi H, Kadowaki T, Fukayama M, Koike K. Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. J Gastroenterol 2018;53:1261-75. [PMID: 29749571 DOI: 10.1007/s00535-018-1472-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
169 Niederreiter L, Tilg H. WITHDRAWN: Cytokines and fatty liver diseases. Liver Research 2018. [DOI: 10.1016/j.livres.2018.01.002] [Reference Citation Analysis]
170 Matsuba I, Matsuba R, Ishibashi S, Yamashita S, Arai H, Yokote K, Suganami H, Araki E. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. J Diabetes Investig 2018;9:1323-32. [PMID: 29603684 DOI: 10.1111/jdi.12845] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
171 Howell GE 3rd, McDevitt E, Henein L, Mulligan C, Young D. "Trans-nonachlor increases extracellular free fatty acid accumulation and de novo lipogenesis to produce hepatic steatosis in McArdle-RH7777 cells". Toxicol In Vitro 2018;50:285-92. [PMID: 29654899 DOI: 10.1016/j.tiv.2018.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
172 Hu XY, Li Y, Li LQ, Zheng Y, Lv JH, Huang SC, Zhang W, Liu L, Zhao L, Liu Z, Zhao XJ. Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey. BMJ Open 2018;8:e019974. [PMID: 29626047 DOI: 10.1136/bmjopen-2017-019974] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
173 Keramida G, Peters AM. Fasting hepatic glucose uptake is higher in men than women. Physiol Rep 2017;5:e13174. [PMID: 28583989 DOI: 10.14814/phy2.13174] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
174 Leibowitz A, Bier A, Gilboa M, Peleg E, Barshack I, Grossman E. Saccharin Increases Fasting Blood Glucose but Not Liver Insulin Resistance in Comparison to a High Fructose-Fed Rat Model. Nutrients 2018;10:E341. [PMID: 29534506 DOI: 10.3390/nu10030341] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
175 Barron L, Courtney C, Bao J, Onufer E, Panni RZ, Aladegbami B, Warner BW. Intestinal resection-associated metabolic syndrome. J Pediatr Surg 2018;53:1142-7. [PMID: 29588076 DOI: 10.1016/j.jpedsurg.2018.02.077] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
176 Ju J, Huang Q, Sun J, Jin Y, Ma W, Song X, Sun H, Wang W. Correlation between PPAR-α methylation level in peripheral blood and inflammatory factors of NAFLD patients with DM. Exp Ther Med 2018;15:1474-8. [PMID: 29434731 DOI: 10.3892/etm.2017.5530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
177 Stewart KJ, Dobrosielski DA. Exercise, Adiposity, and Regional Fat Distribution. Contemporary Diabetes 2018. [DOI: 10.1007/978-3-319-61013-9_10] [Reference Citation Analysis]
178 Farrell GC, Haczeyni F, Chitturi S. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. Adv Exp Med Biol 2018;1061:19-44. [PMID: 29956204 DOI: 10.1007/978-981-10-8684-7_3] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 16.4] [Reference Citation Analysis]
179 Wu L, Zhu X, Fan L, Kabagambe EK, Song Y, Tao M, Zhong X, Hou L, Shrubsole MJ, Liu J, Dai Q. Magnesium intake and mortality due to liver diseases: Results from the Third National Health and Nutrition Examination Survey Cohort. Sci Rep 2017;7:17913. [PMID: 29263344 DOI: 10.1038/s41598-017-18076-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
180 Tsai CY, Nojiri M, Yokoyama Y, Ebata T, Mizuno T, Nagino M. Uneven acute non-alcoholic fatty change of the liver after percutaneous transhepatic portal vein embolization in a patient with hilar cholangiocarcinoma - a case report. BMC Gastroenterol 2017;17:144. [PMID: 29207941 DOI: 10.1186/s12876-017-0715-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
181 Fakhoury-Sayegh N, Younes H, Heraoui GNHA, Sayegh R. Nutritional Profile and Dietary Patterns of Lebanese Non-Alcoholic Fatty Liver Disease Patients: A Case-Control Study. Nutrients 2017;9:E1245. [PMID: 29135945 DOI: 10.3390/nu9111245] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
182 Argo CK, Henry ZH, Caldwell SH. Nonalcoholic Fatty Liver Disease. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
183 Bubnov RV, Babenko LP, Lazarenko LM, Mokrozub VV, Demchenko OA, Nechypurenko OV, Spivak MY. Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice. EPMA J 2017;8:357-76. [PMID: 29209439 DOI: 10.1007/s13167-017-0117-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 7.5] [Reference Citation Analysis]
184 Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol 2017; 23(36): 6571-6592 [PMID: 29085206 DOI: 10.3748/wjg.v23.i36.6571] [Cited by in CrossRef: 108] [Cited by in F6Publishing: 113] [Article Influence: 18.0] [Reference Citation Analysis]
185 Ohmi S, Ono M, Takata H, Hirano S, Funakoshi S, Nishi Y, Yoshimura K, Amano E, Terada Y, Saibara T, Fujimoto S. Analysis of factors influencing glucose tolerance in Japanese patients with non-alcoholic fatty liver disease. Diabetol Metab Syndr 2017;9. [DOI: 10.1186/s13098-017-0264-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
186 Manco M. Insulin Resistance and NAFLD: A Dangerous Liaison beyond the Genetics. Children (Basel) 2017;4:E74. [PMID: 28805745 DOI: 10.3390/children4080074] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
187 Tilg H. How to Approach a Patient With Nonalcoholic Fatty Liver Disease. Gastroenterology 2017;153:345-9. [PMID: 28647352 DOI: 10.1053/j.gastro.2017.06.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
188 Hua MC, Su HM, Yao TC, Kuo ML, Lai MW, Tsai MH, Huang JL. Alternation of plasma fatty acids composition and desaturase activities in children with liver steatosis. PLoS One 2017;12:e0182277. [PMID: 28759573 DOI: 10.1371/journal.pone.0182277] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
189 Dongiovanni P, Valenti L. A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2017;18:E1534. [PMID: 28714900 DOI: 10.3390/ijms18071534] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
190 Moon J, Kim OY, Jo G, Shin MJ. Alterations in Circulating Amino Acid Metabolite Ratio Associated with Arginase Activity Are Potential Indicators of Metabolic Syndrome: The Korean Genome and Epidemiology Study. Nutrients 2017;9:E740. [PMID: 28704931 DOI: 10.3390/nu9070740] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
191 Bouchi R, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y. Gender difference in the impact of gynoid and android fat masses on the progression of hepatic steatosis in Japanese patients with type 2 diabetes. BMC Obes 2017;4:27. [PMID: 28702206 DOI: 10.1186/s40608-017-0163-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
192 Masarone M, Rosato V, Aglitti A, Bucci T, Caruso R, Salvatore T, Sasso FC, Tripodi MF, Persico M. Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. PLoS One 2017;12:e0178473. [PMID: 28570615 DOI: 10.1371/journal.pone.0178473] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 9.8] [Reference Citation Analysis]
193 Petersen MC, Shulman GI. Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. Trends Pharmacol Sci. 2017;38:649-665. [PMID: 28551355 DOI: 10.1016/j.tips.2017.04.004] [Cited by in Crossref: 190] [Cited by in F6Publishing: 194] [Article Influence: 31.7] [Reference Citation Analysis]
194 Abdel Monem SM. Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals. Euroasian J Hepatogastroenterol 2017;7:101-6. [PMID: 29201787 DOI: 10.5005/jp-journals-10018-1226] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
195 Kim GW, Jo HK, Chung SH. Ginseng seed oil ameliorates hepatic lipid accumulation in vitro and in vivo. J Ginseng Res 2018;42:419-28. [PMID: 30344430 DOI: 10.1016/j.jgr.2017.04.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
196 Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients 2017;9:E387. [PMID: 28420094 DOI: 10.3390/nu9040387] [Cited by in Crossref: 239] [Cited by in F6Publishing: 253] [Article Influence: 39.8] [Reference Citation Analysis]
197 Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197-211. [PMID: 28303724 DOI: 10.1080/03602532.2017.1293683] [Cited by in Crossref: 240] [Cited by in F6Publishing: 197] [Article Influence: 40.0] [Reference Citation Analysis]
198 Wainwright P, Scorletti E, Byrne CD. Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. Curr Diab Rep 2017;17. [DOI: 10.1007/s11892-017-0851-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
199 Colić M. Connection between nonalcoholic fatty liver disease and arterial hypertension. Cardiologia Croatica 2017;12:86-86. [DOI: 10.15836/ccar2017.86] [Reference Citation Analysis]
200 Parséus A, Sommer N, Sommer F, Caesar R, Molinaro A, Ståhlman M, Greiner TU, Perkins R, Bäckhed F. Microbiota-induced obesity requires farnesoid X receptor. Gut 2017;66:429-37. [PMID: 26740296 DOI: 10.1136/gutjnl-2015-310283] [Cited by in Crossref: 280] [Cited by in F6Publishing: 284] [Article Influence: 46.7] [Reference Citation Analysis]
201 Volkova NI, Porksheyan MI. Nonalcoholic fatty liver disease: What do we know and what will we have to learn? Terapevticheskii arkhiv 2017;89:91-98. [DOI: 10.17116/terarkh201789291-98] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
202 Davoodi I, Rahimi R, Abdollahi M, Farzaei F, Farzaei MH, Memariani Z, Najafi F. Promising effect of Rosa damascena extract on high-fat diet-induced nonalcoholic fatty liver. J Tradit Complement Med 2017;7:508-14. [PMID: 29034200 DOI: 10.1016/j.jtcme.2017.01.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
203 Qian LY, Tu JF, Ding YH, Pang J, Che XD, Zou H, Huang DS. Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population: Normal is not the new normal. Medicine (Baltimore) 2016;95:e4293. [PMID: 27442673 DOI: 10.1097/MD.0000000000004293] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
204 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 505] [Cited by in F6Publishing: 483] [Article Influence: 84.2] [Reference Citation Analysis]
205 Gawrieh S. Nonalcoholic Fatty Liver Disease. Liver Disorders 2017. [DOI: 10.1007/978-3-319-30103-7_14] [Reference Citation Analysis]
206 Kim JW, Kim SM, Heo SH, Kim JW, Shin SS, Jeong YY, Jeong GW, Kang HK. Effect of Gadoxetic Acid on Quantification of Hepatic Steatosis Using Magnetic Resonance Spectroscopy: A Prospective Study. J Korean Soc Radiol 2017;76:237. [DOI: 10.3348/jksr.2017.76.4.237] [Reference Citation Analysis]
207 Cusi K. Nonalcoholic steatohepatitis in nonobese patients: Not so different after all. Hepatology 2017;65:4-7. [PMID: 27650699 DOI: 10.1002/hep.28839] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
208 Connor L, Fink SA. NASH: The Ethical Dilemma. Contemporary Liver Transplantation 2017. [DOI: 10.1007/978-3-319-07209-8_15] [Reference Citation Analysis]
209 Jiang W, Guo MH, Hai X. Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat. World J Gastroenterol 2016; 22(46): 10180-10188 [PMID: 28028366 DOI: 10.3748/wjg.v22.i46.10180] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 80] [Article Influence: 11.6] [Reference Citation Analysis]
210 Lau JK, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241:36-44. [PMID: 27757953 DOI: 10.1002/path.4829] [Cited by in Crossref: 193] [Cited by in F6Publishing: 201] [Article Influence: 27.6] [Reference Citation Analysis]
211 Keramida G, Hunter J, Peters AM. Hepatic glucose utilization in hepatic steatosis and obesity. Biosci Rep 2016;36:e00402. [PMID: 27653524 DOI: 10.1042/BSR20160381] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
212 Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. Hepatol Res 2016;46:1226-33. [PMID: 26866817 DOI: 10.1111/hepr.12671] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 8.7] [Reference Citation Analysis]
213 Xu ZJ, Shi JP, Yu DR, Zhu LJ, Jia JD, Fan JG. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design. Adv Ther 2016;33:2069-81. [PMID: 27743352 DOI: 10.1007/s12325-016-0416-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
214 Lei FF, Li YJ, Li RG, Li G, Li JK, Li F, Tan HB. Mechanism underlying protective effect of gypenosides against type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats. Shijie Huaren Xiaohua Zazhi 2016; 24(30): 4169-4176 [DOI: 10.11569/wcjd.v24.i30.4169] [Reference Citation Analysis]
215 Petersen MC, Madiraju AK, Gassaway BM, Marcel M, Nasiri AR, Butrico G, Marcucci MJ, Zhang D, Abulizi A, Zhang XM, Philbrick W, Hubbard SR, Jurczak MJ, Samuel VT, Rinehart J, Shulman GI. Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. J Clin Invest 2016;126:4361-71. [PMID: 27760050 DOI: 10.1172/JCI86013] [Cited by in Crossref: 140] [Cited by in F6Publishing: 140] [Article Influence: 20.0] [Reference Citation Analysis]
216 Gliozzi M, Maiuolo J, Oppedisano F, Mollace V. The effect of bergamot polyphenolic fraction in patients with non alcoholic liver steato-hepatitis and metabolic syndrome. PharmaNutrition 2016;4:S27-31. [DOI: 10.1016/j.phanu.2015.11.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
217 Misciagna G, del Pilar Díaz M, Caramia DV, Bonfiglio C, Franco I, Noviello MR, Chiloiro M, Abbrescia DI, Mirizzi A, Tanzi M, Caruso MG, Correale M, Reddavide R, Inguaggiato R, Cisternino AM, Osella AR. Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial. J Nutr Health Aging 2017;21:404-12. [DOI: 10.1007/s12603-016-0809-8] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 9.7] [Reference Citation Analysis]
218 Isaksen VT, Larsen MA, Goll R, Florholmen JR, Paulssen EJ. Hepatic steatosis, detected by hepatorenal index in ultrasonography, as a predictor of insulin resistance in obese subjects. BMC Obes 2016;3:39. [PMID: 27672441 DOI: 10.1186/s40608-016-0118-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
219 Grander C, Grabherr F, Moschen AR, Tilg H. Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. Visc Med 2016;32:329-34. [PMID: 27921044 DOI: 10.1159/000448940] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
220 Margolis LM, Rivas DA, Ezzyat Y, Gaffney-Stomberg E, Young AJ, McClung JP, Fielding RA, Pasiakos SM. Calorie Restricted High Protein Diets Downregulate Lipogenesis and Lower Intrahepatic Triglyceride Concentrations in Male Rats. Nutrients 2016;8:E571. [PMID: 27649241 DOI: 10.3390/nu8090571] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
221 Kim MK, Ahn CW, Nam JS, Kang S, Park JS, Kim KR. Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women. Menopause 2015;22:1323-7. [PMID: 26154274 DOI: 10.1097/GME.0000000000000503] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
222 Chen S, Guo X, Yu S, Sun G, Yang H, Li Z, Sun Y. Association between Serum Uric Acid and Elevated Alanine Aminotransferase in the General Population. Int J Environ Res Public Health 2016;13:E841. [PMID: 27563918 DOI: 10.3390/ijerph13090841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
223 Harris K, Desai N, Gupta M, Xue X, Chatterjee PK, Rochelson B, Metz CN. The effects of prenatal metformin on obesogenic diet-induced alterations in maternal and fetal fatty acid metabolism. Nutr Metab (Lond) 2016;13:55. [PMID: 27555877 DOI: 10.1186/s12986-016-0115-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
224 Smith SI. PPAR-γ receptor agonists-a review of their role in diabetic management in Trinidad and Tobago. Mol Cell Biochem 2004;263:189-210. [PMID: 27520678 DOI: 10.1023/B:MCBI.0000041861.79585.4b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
225 Ducheix S, Vegliante MC, Villani G, Napoli N, Sabbà C, Moschetta A. Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β. Cell Mol Life Sci 2016;73:3809-22. [PMID: 27522544 DOI: 10.1007/s00018-016-2331-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
226 Botezelli JD, Coope A, Ghezzi AC, Cambri LT, Moura LP, Scariot PP, Gaspar RS, Mekary RA, Ropelle ER, Pauli JR. Strength Training Prevents Hyperinsulinemia, Insulin Resistance, and Inflammation Independent of Weight Loss in Fructose-Fed Animals. Sci Rep 2016;6:31106. [PMID: 27487746 DOI: 10.1038/srep31106] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
227 Rebalka IA, Raleigh MJ, Snook LA, Rebalka AN, MacPherson RE, Wright DC, Schertzer JD, Hawke TJ. Statin Therapy Alters Lipid Storage in Diabetic Skeletal Muscle. Front Endocrinol (Lausanne) 2016;7:95. [PMID: 27486434 DOI: 10.3389/fendo.2016.00095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
228 Kitagawa N, Ninomiya K, Okugawa S, Motai C, Nakanishi Y, Yoshikawa M, Muraoka O, Morikawa T. Quantitative Determination of Principal Alkaloid and Flavonoid Constituents in Wintersweet, the Flower Buds of Chimonanthus praecox. Natural Product Communications 2016;11:1934578X1601100. [DOI: 10.1177/1934578x1601100721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
229 Emamat H, Noori M, Foroughi F, Rismanchi M, Eini-Zinab H, Hekmatdoost A. An Accessible and Pragmatic Experimental Model of Nonalcoholic Fatty Liver Disease. Middle East J Dig Dis. 2016;8:109-115. [PMID: 27252817 DOI: 10.15171/mejdd.2016.15] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
230 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol. 2016;7:211-217. [PMID: 27189281 DOI: 10.3349/ymj.2016.57.4.885] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
231 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016; 7(2): 211-217 [PMID: 27190693 DOI: 10.4291/wjgp.v7.i2.211] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 7.7] [Reference Citation Analysis]
232 Um ES, Kim YC. Effect of Samhwangsasim-tang and Daehwanghwangryunsasim-tang on Palmitate-induced Lipogenesis in HepG2 cells. J Korean Med 2016;37:62-76. [DOI: 10.13048/jkm.16007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
233 Perticone M, Cimellaro A, Maio R, Caroleo B, Sciacqua A, Sesti G, Perticone F. Additive Effect of Non-Alcoholic Fatty Liver Disease on Metabolic Syndrome-Related Endothelial Dysfunction in Hypertensive Patients. Int J Mol Sci 2016;17:456. [PMID: 27023537 DOI: 10.3390/ijms17040456] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
234 Ande SR, Nguyen KH, Grégoire Nyomba BL, Mishra S. Prohibitin-induced, obesity-associated insulin resistance and accompanying low-grade inflammation causes NASH and HCC. Sci Rep 2016;6:23608. [PMID: 27005704 DOI: 10.1038/srep23608] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
235 Foroughi M, Maghsoudi Z, Askari G. The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iran J Nurs Midwifery Res 2016;21:100-4. [PMID: 26985230 DOI: 10.4103/1735-9066.174759] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
236 Fujibayashi K, Gunji T, Yokokawa H, Naito T, Sasabe N, Okumura M, Iijima K, Shibuya K, Hisaoka T, Fukuda H. The Relationships between Metabolic Disorders (Hypertension, Dyslipidemia, and Impaired Glucose Tolerance) and Computed Tomography-Based Indices of Hepatic Steatosis or Visceral Fat Accumulation in Middle-Aged Japanese Men. PLoS One 2016;11:e0149689. [PMID: 26938785 DOI: 10.1371/journal.pone.0149689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
237 Rasineni K, Penrice DD, Natarajan SK, McNiven MA, McVicker BL, Kharbanda KK, Casey CA, Harris EN. Alcoholic vs non-alcoholic fatty liver in rats: distinct differences in endocytosis and vesicle trafficking despite similar pathology. BMC Gastroenterol. 2016;16:27. [PMID: 26924554 DOI: 10.1186/s12876-016-0433-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
238 Alkhatatbeh MJ, Lincz LF, Thorne RF. Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease. Exp Ther Med 2016;11:1487-92. [PMID: 27073470 DOI: 10.3892/etm.2016.3069] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
239 Sayej WN, Knight Iii PR, Guo WA, Mullan B, Ohtake PJ, Davidson BA, Khan A, Baker RD, Baker SS. Advanced Glycation End Products Induce Obesity and Hepatosteatosis in CD-1 Wild-Type Mice. Biomed Res Int. 2016;2016:7867852. [PMID: 26942201 DOI: 10.1155/2016/7867852] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
240 Hamed SA, Fathy RA, Radwan ME, Abdellah MM. Fatty liver in adults receiving antiepileptic medications: relationship to the metabolic risks. Expert Rev Clin Pharmacol 2016;9:617-24. [PMID: 26652506 DOI: 10.1586/17512433.2016.1131123] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
241 Sakai H, Shirakami Y, Shimizu M. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World J Gastroenterol 2016; 22(1): 394-406 [PMID: 26755885 DOI: 10.3748/wjg.v22.i1.394] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
242 Connor L, Fink SA. NASH, The Ethical Dilemma. Contemporary Liver Transplantation 2016. [DOI: 10.1007/978-3-319-05543-5_15-2] [Reference Citation Analysis]
243 Gawrieh S, Chalasani N. Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease. Alcoholic and Non-Alcoholic Fatty Liver Disease 2016. [DOI: 10.1007/978-3-319-20538-0_16] [Reference Citation Analysis]
244 Zhang D, Yin L. Transcriptional Regulation of De Novo Lipogenesis in Liver. Hepatic De Novo Lipogenesis and Regulation of Metabolism 2016. [DOI: 10.1007/978-3-319-25065-6_1] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
245 Robertson CL, Sarkar D, Sanyal AJ. Obesity, NASH, and HCC. Hepatocellular Carcinoma 2016. [DOI: 10.1007/978-3-319-34214-6_18] [Reference Citation Analysis]
246 Vasendin DV. Structural changes in the liver in metabolic syndrome. Uč zap St -Peterbg gos med univ im Akad I P Pavlova 2015;22:20-27. [DOI: 10.24884/1607-4181-2015-22-4-20-27] [Reference Citation Analysis]
247 John K, Marino JS, Sanchez ER, Hinds TD Jr. The glucocorticoid receptor: cause of or cure for obesity? Am J Physiol Endocrinol Metab 2016;310:E249-57. [PMID: 26714851 DOI: 10.1152/ajpendo.00478.2015] [Cited by in Crossref: 86] [Cited by in F6Publishing: 90] [Article Influence: 10.8] [Reference Citation Analysis]
248 Lima ML, Leite LH, Gioda CR, Leme FO, Couto CA, Coimbra CC, Leite VH, Ferrari TC. A Novel Wistar Rat Model of Obesity-Related Nonalcoholic Fatty Liver Disease Induced by Sucrose-Rich Diet. J Diabetes Res 2016;2016:9127076. [PMID: 26788524 DOI: 10.1155/2016/9127076] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
249 Ideta T, Shirakami Y, Miyazaki T, Kochi T, Sakai H, Moriwaki H, Shimizu M. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. Int J Mol Sci 2015;16:29207-18. [PMID: 26670228 DOI: 10.3390/ijms161226156] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
250 Shadab Siddiqui M, Sanyal AJ. Nonalcoholic Fatty Liver Disease. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch104] [Reference Citation Analysis]
251 Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A. Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 2016;11:3-10. [PMID: 26602387 DOI: 10.1007/s11739-015-1346-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
252 Rahimlou M, Ahmadnia H, Hekmatdoost A. Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. World J Hepatol 2015; 7(25): 2597-2602 [PMID: 26557952 DOI: 10.4254/wjh.v7.i25.2597] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
253 Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(39): 11053-11076 [PMID: 26494962 DOI: 10.3748/wjg.v21.i39.11053] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
254 Turecký L, Kupčová V, Uhlíková E, Mojto V. Peroxisomal enzymes in the liver of rats with experimental diabetes mellitus type 2. Physiol Res 2014;63:S585-91. [PMID: 25669689 DOI: 10.33549/physiolres.932918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
255 Rantakokko P, Männistö V, Airaksinen R, Koponen J, Viluksela M, Kiviranta H, Pihlajamäki J. Persistent organic pollutants and non-alcoholic fatty liver disease in morbidly obese patients: a cohort study. Environ Health 2015;14:79. [PMID: 26420011 DOI: 10.1186/s12940-015-0066-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
256 Brina D, Miluzio A, Ricciardi S, Clarke K, Davidsen PK, Viero G, Tebaldi T, Offenhäuser N, Rozman J, Rathkolb B, Neschen S, Klingenspor M, Wolf E, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Quattrone A, Falciani F, Biffo S. eIF6 coordinates insulin sensitivity and lipid metabolism by coupling translation to transcription. Nat Commun 2015;6:8261. [PMID: 26383020 DOI: 10.1038/ncomms9261] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 8.4] [Reference Citation Analysis]
257 Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D, Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015;63:705-12. [PMID: 25980762 DOI: 10.1016/j.jhep.2015.05.006] [Cited by in Crossref: 248] [Cited by in F6Publishing: 247] [Article Influence: 31.0] [Reference Citation Analysis]
258 Edelman D, Kalia H, Delio M, Alani M, Krishnamurthy K, Abd M, Auton A, Wang T, Wolkoff AW, Morrow BE. Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population. Mol Genet Genomic Med 2015;3:558-69. [PMID: 26740948 DOI: 10.1002/mgg3.168] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
259 Lautt W, Ming Z, Legare D, Chowdhury K, Hatch G, Wang H. Fatty Liver and Fatty Heart—Where do They Stand in the AMIS Syndrome? Healthcare 2015;3:666-682. [DOI: 10.3390/healthcare3030666] [Reference Citation Analysis]
260 Dongiovanni P, Romeo S, Valenti L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int 2015;2015:460190. [PMID: 26273621 DOI: 10.1155/2015/460190] [Cited by in Crossref: 91] [Cited by in F6Publishing: 97] [Article Influence: 11.4] [Reference Citation Analysis]
261 Povero D, Panera N, Eguchi A, Johnson CD, Papouchado BG, de Araujo Horcel L, Pinatel EM, Alisi A, Nobili V, Feldstein AE. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ. Cell Mol Gastroenterol Hepatol 2015;1:646-663.e4. [PMID: 26783552 DOI: 10.1016/j.jcmgh.2015.07.007] [Cited by in Crossref: 115] [Cited by in F6Publishing: 120] [Article Influence: 14.4] [Reference Citation Analysis]
262 Zhou Y, He CH, Herzog EL, Peng X, Lee CM, Nguyen TH, Gulati M, Gochuico BR, Gahl WA, Slade ML, Lee CG, Elias JA. Chitinase 3-like-1 and its receptors in Hermansky-Pudlak syndrome-associated lung disease. J Clin Invest 2015;125:3178-92. [PMID: 26121745 DOI: 10.1172/JCI79792] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
263 Yang CQ, Shu L, Wang S, Wang JJ, Zhou Y, Xuan YJ, Wang SF. Dietary Patterns Modulate the Risk of Non-Alcoholic Fatty Liver Disease in Chinese Adults. Nutrients 2015;7:4778-91. [PMID: 26083112 DOI: 10.3390/nu7064778] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]
264 Hui ST, Parks BW, Org E, Norheim F, Che N, Pan C, Castellani LW, Charugundla S, Dirks DL, Psychogios N, Neuhaus I, Gerszten RE, Kirchgessner T, Gargalovic PS, Lusis AJ. The genetic architecture of NAFLD among inbred strains of mice. Elife 2015;4:e05607. [PMID: 26067236 DOI: 10.7554/eLife.05607] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 8.5] [Reference Citation Analysis]
265 Liu Z, Patil IY, Jiang T, Sancheti H, Walsh JP, Stiles BL, Yin F, Cadenas E. High-fat diet induces hepatic insulin resistance and impairment of synaptic plasticity. PLoS One 2015;10:e0128274. [PMID: 26023930 DOI: 10.1371/journal.pone.0128274] [Cited by in Crossref: 112] [Cited by in F6Publishing: 126] [Article Influence: 14.0] [Reference Citation Analysis]
266 Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 2015;21:4103-10. [PMID: 25892859 DOI: 10.3748/wjg.v21.i14.4103] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 114] [Article Influence: 13.3] [Reference Citation Analysis]
267 Reis SR, Feres NH, Ignacio-Souza LM, Veloso RV, Arantes VC, Kawashita NH, Colodel EM, Botosso BL, Reis MA, Latorraca MQ. Nutritional recovery with a soybean diet after weaning reduces lipogenesis but induces inflammation in the liver in adult rats exposed to protein restriction during intrauterine life and lactation. Mediators Inflamm 2015;2015:781703. [PMID: 25892856 DOI: 10.1155/2015/781703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
268 Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol 2015; 7(3): 575-582 [PMID: 25848481 DOI: 10.4254/wjh.v7.i3.575] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
269 Ahmed MH, Husain NE, Almobarak AO. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians? J Family Med Prim Care. 2015;4:45-52. [PMID: 25810989 DOI: 10.4103/2249-4863.152252] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
270 Hu C, Wang Y, Fan Y, Li H, Wang C, Zhang J, Zhang S, Han X, Wen C. Lipidomics revealed idiopathic pulmonary fibrosis-induced hepatic lipid disorders corrected with treatment of baicalin in a murine model. AAPS J 2015;17:711-22. [PMID: 25762447 DOI: 10.1208/s12248-014-9714-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
271 Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015;47:181-90. [PMID: 25739820 DOI: 10.1016/j.dld.2014.09.020] [Cited by in Crossref: 451] [Cited by in F6Publishing: 465] [Article Influence: 56.4] [Reference Citation Analysis]
272 Wu CC, Weng WL, Lai WL, Tsai HP, Liu WH, Lee MH, Tsai YC. Effect of Lactobacillus plantarum Strain K21 on High-Fat Diet-Fed Obese Mice. Evid Based Complement Alternat Med 2015;2015:391767. [PMID: 25802537 DOI: 10.1155/2015/391767] [Cited by in Crossref: 33] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
273 He Q, Li JK, Li F, Li RG, Zhan GQ, Li G, Du WX, Tan HB. Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats. World J Gastroenterol 2015; 21(7): 2058-2066 [PMID: 25717238 DOI: 10.3748/wjg.v21.i7.2058] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
274 Tortora R, Capone P, De Stefano G, Imperatore N, Gerbino N, Donetto S, Monaco V, Caporaso N, Rispo A. Metabolic syndrome in patients with coeliac disease on a gluten-free diet. Aliment Pharmacol Ther 2015;41:352-9. [PMID: 25581084 DOI: 10.1111/apt.13062] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 10.9] [Reference Citation Analysis]
275 Aroor AR, Habibi J, Ford DA, Nistala R, Lastra G, Manrique C, Dunham MM, Ford KD, Thyfault JP, Parks EJ. Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function. Diabetes. 2015;64:1988-2001. [PMID: 25605806 DOI: 10.2337/db14-0804] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 7.8] [Reference Citation Analysis]
276 Connor L, Fink SA. NASH, The Ethical Dilemma. Contemporary Liver Transplantation 2015. [DOI: 10.1007/978-3-319-05543-5_15-1] [Reference Citation Analysis]
277 Cho JH, Namgung JS, Lee J, Moon DH, Lee HK. Analysis of biochemical markers related to Fatty liver patients. J Phys Ther Sci 2014;26:1865-8. [PMID: 25540483 DOI: 10.1589/jpts.26.1865] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
278 Xia J, Yuan J, Xin L, Zhang Y, Kong S, Chen Y, Yang S, Li K. Transcriptome analysis on the inflammatory cell infiltration of nonalcoholic steatohepatitis in bama minipigs induced by a long-term high-fat, high-sucrose diet. PLoS One 2014;9:e113724. [PMID: 25415189 DOI: 10.1371/journal.pone.0113724] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
279 Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Mon 2014;14:e23235. [PMID: 25598791 DOI: 10.5812/hepatmon.23235] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 6.0] [Reference Citation Analysis]
280 Sawhney A, Rothkopf M. Metabolic Syndrome. Metabolic Medicine and Surgery 2014. [DOI: 10.1201/b17616-7] [Reference Citation Analysis]
281 Yao J, Zhou CS, Ma X, Fu BQ, Tao LS, Chen M, Xu YP. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol 2014; 20(39): 14430-14441 [PMID: 25339829 DOI: 10.3748/wjg.v20.i39.14430] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
282 Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World J Gastroenterol 2014; 20(36): 12945-12955 [PMID: 25278690 DOI: 10.3748/wjg.v20.i36.12945] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 96] [Article Influence: 10.2] [Reference Citation Analysis]
283 Hassanin A, Malek HA, Saleh D. Heparin modulation on hepatic nitric oxide synthase in experimental steatohepatitis. Exp Ther Med 2014;8:1551-8. [PMID: 25289058 DOI: 10.3892/etm.2014.1963] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
284 Ferrajolo C, Coloma PM, Verhamme KM, Schuemie MJ, de Bie S, Gini R, Herings R, Mazzaglia G, Picelli G, Giaquinto C. Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. Drug Saf. 2014;37:99-108. [PMID: 24446276 DOI: 10.1007/s40264-013-0132-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
285 Rahimi Naini S, Fuchs M. Non-alcoholic fatty liver disease in patients with diabetes mellitus. Expert Rev Endocrinol Metab 2014;9:503-14. [PMID: 30736212 DOI: 10.1586/17446651.2014.938053] [Reference Citation Analysis]
286 Dhital R, Tirosh O. Fatty Liver Vulnerability to Hypoxic and Inflammatory Stress. Oxidative Stress and Disease 2014. [DOI: 10.1201/b17315-5] [Reference Citation Analysis]
287 Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocellular Carcinoma. 2014;1:115-125. [PMID: 27508181 DOI: 10.2147/jhc.s44381] [Cited by in Crossref: 59] [Cited by in F6Publishing: 70] [Article Influence: 6.6] [Reference Citation Analysis]
288 van der Veen JN, Lingrell S, da Silva RP, Jacobs RL, Vance DE. The concentration of phosphatidylethanolamine in mitochondria can modulate ATP production and glucose metabolism in mice. Diabetes 2014;63:2620-30. [PMID: 24677714 DOI: 10.2337/db13-0993] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 7.0] [Reference Citation Analysis]
289 Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M; EPE-A Study Group. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014;147:377-84.e1. [PMID: 24818764 DOI: 10.1053/j.gastro.2014.04.046] [Cited by in Crossref: 219] [Cited by in F6Publishing: 226] [Article Influence: 24.3] [Reference Citation Analysis]
290 Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol 2014; 20(26): 8351-8363 [PMID: 25024594 DOI: 10.3748/wjg.v20.i26.8351] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 89] [Article Influence: 9.7] [Reference Citation Analysis]
291 Smith RJ. Nutrition and metabolism in hepatocellular carcinoma. Hepatobiliary Surg Nutr 2013;2:89-96. [PMID: 24570922 DOI: 10.3978/j.issn.2304-3881.2012.11.02] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
292 Blaslov K, Bulum T, Zibar K, Duvnjak L. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7356-7365 [PMID: 24966606 DOI: 10.3748/wjg.v20.i23.7356] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
293 Lee HS, Son WC, Ryu JE, Koo BA, Kim YS. Standardized Salvia miltiorrhiza extract suppresses hepatic stellate cell activation and attenuates steatohepatitis induced by a methionine-choline deficient diet in mice. Molecules. 2014;19:8189-8211. [PMID: 24941342 DOI: 10.3390/molecules19068189] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
294 Feng B, He Q, Xu H. FOXO1-dependent up-regulation of MAP kinase phosphatase 3 (MKP-3) mediates glucocorticoid-induced hepatic lipid accumulation in mice. Mol Cell Endocrinol 2014;393:46-55. [PMID: 24946098 DOI: 10.1016/j.mce.2014.06.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
295 Kim EJ, Kim BH, Seo HS, Lee YJ, Kim HH, Son HH, Choi MH. Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation. PLoS One 2014;9:e97841. [PMID: 24901254 DOI: 10.1371/journal.pone.0097841] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
296 Han Y, Lin M, Wang X, Guo K, Wang S, Sun M, Wang J, Han X, Fu T, Hu Y, Fu J. Basis of aggravated hepatic lipid metabolism by chronic stress in high-fat diet-fed rat. Endocrine 2015;48:483-92. [PMID: 24895043 DOI: 10.1007/s12020-014-0307-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
297 Zhu LH, Wang A, Luo P, Wang X, Jiang DS, Deng W, Zhang X, Wang T, Liu Y, Gao L, Zhang S, Zhang X, Zhang J, Li H. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice. J Hepatol 2014;60:1046-54. [PMID: 24445216 DOI: 10.1016/j.jhep.2014.01.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
298 Beaven SW, Matveyenko A, Wroblewski K, Chao L, Wilpitz D, Hsu TW, Lentz J, Drew B, Hevener AL, Tontonoz P. Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell Metab 2013;18:106-17. [PMID: 23823481 DOI: 10.1016/j.cmet.2013.04.021] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 11.3] [Reference Citation Analysis]
299 Yaligar J, Gopalan V, Kiat OW, Sugii S, Shui G, Lam BD, Henry CJ, Wenk MR, Tai ES, Velan SS. Evaluation of dietary effects on hepatic lipids in high fat and placebo diet fed rats by in vivo MRS and LC-MS techniques. PLoS One 2014;9:e91436. [PMID: 24638096 DOI: 10.1371/journal.pone.0091436] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
300 Ha V, Jayalath VH, Cozma AI, Mirrahimi A, de Souza RJ, Sievenpiper JL. Fructose-containing sugars, blood pressure, and cardiometabolic risk: a critical review. Curr Hypertens Rep 2013;15:281-97. [PMID: 23793849 DOI: 10.1007/s11906-013-0364-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
301 Asai A, Chou PM, Bu HF, Wang X, Rao MS, Jiang A, DiDonato CJ, Tan XD. Dissociation of hepatic insulin resistance from susceptibility of nonalcoholic fatty liver disease induced by a high-fat and high-carbohydrate diet in mice. Am J Physiol Gastrointest Liver Physiol 2014;306:G496-504. [PMID: 24436353 DOI: 10.1152/ajpgi.00291.2013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
302 Chen G, Chen L, Huang B, Qiu C, Lu J, Bi Y, Ning G, Liang J, Wen J. Is alanine aminotransferase associated with osteopenia in middle-aged and elderly Chinese? Endocr Pract 2014;20:775-84. [PMID: 24518175 DOI: 10.4158/EP13166.OR] [Reference Citation Analysis]
303 Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des. 2013;19:5219-5238. [PMID: 23394097 DOI: 10.2174/13816128113199990381] [Cited by in Crossref: 142] [Cited by in F6Publishing: 153] [Article Influence: 15.8] [Reference Citation Analysis]
304 Partridge CG, Fawcett GL, Wang B, Semenkovich CF, Cheverud JM. The effect of dietary fat intake on hepatic gene expression in LG/J AND SM/J mice. BMC Genomics 2014;15:99. [PMID: 24499025 DOI: 10.1186/1471-2164-15-99] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
305 Morling JR, Fallowfield JA, Guha IN, Nee LD, Glancy S, Williamson RM, Robertson CM, Strachan MW, Price JF; Edinburgh Type 2 Diabetes Study investigators. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. J Hepatol 2014;60:384-91. [PMID: 24512822 DOI: 10.1016/j.jhep.2013.10.017] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
306 Jiang ZG, Mukamal K, Tapper E, Robson SC, Tsugawa Y. Low LDL-C and high HDL-C levels are associated with elevated serum transaminases amongst adults in the United States: a cross-sectional study. PLoS One 2014;9:e85366. [PMID: 24454851 DOI: 10.1371/journal.pone.0085366] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
307 Darling JN, Ross AP, Bartness TJ, Parent MB. Predicting the effects of a high-energy diet on fatty liver and hippocampal-dependent memory in male rats. Obesity (Silver Spring) 2013;21:910-7. [PMID: 23784893 DOI: 10.1002/oby.20167] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
308 Lu Y, Ma Z, Zhang Z, Xiong X, Wang X, Zhang H, Shi G, Xia X, Ning G, Li X. Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. Gut 2014;63:170-8. [PMID: 23348961 DOI: 10.1136/gutjnl-2012-303150] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 7.6] [Reference Citation Analysis]
309 Baffy G. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. J Clin Transl Hepatol 2013;1:131-7. [PMID: 26355775 DOI: 10.14218/JCTH.2013.00005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 28] [Article Influence: 0.8] [Reference Citation Analysis]
310 Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol. 2014;36:115-132. [PMID: 24337650 DOI: 10.1007/s00281-013-0404-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
311 Mohan G, Bhalla N, Kaur R, Singh H. TO STUDY THE PREVALENCE OF NON ALCOHOLIC FATTY LIVER DISEASE AND ITS CORRELATION WITH METABOLIC SYNDROME. jemds 2013;2:9707-9715. [DOI: 10.14260/jemds/1681] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
312 Tao C, Sifuentes A, Holland WL. Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes. Best Pract Res Clin Endocrinol Metab. 2014;28:43-58. [PMID: 24417945 DOI: 10.1016/j.beem.2013.11.003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 8.0] [Reference Citation Analysis]
313 Valenti L, Riso P, Mazzocchi A, Porrini M, Fargion S, Agostoni C. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2013;2013:145421. [PMID: 24282628 DOI: 10.1155/2013/145421] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 8.2] [Reference Citation Analysis]
314 Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, O'Dea K, Desmond PV, Johnson NA, Wilson AM. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013;59:138-43. [PMID: 23485520 DOI: 10.1016/j.jhep.2013.02.012] [Cited by in Crossref: 420] [Cited by in F6Publishing: 430] [Article Influence: 42.0] [Reference Citation Analysis]
315 Latea L, Negrea S, Bolboaca S. Primary non-alcoholic fatty liver disease in hypertensive patients. Australas Med J 2013;6:325-30. [PMID: 23837080 DOI: 10.4066/AMJ.2013.1648] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
316 Ju DY, Choe YG, Cho YK, Shin DS, Yoo SH, Yim SH, Lee JY, Park JH, Kim HJ, Park DI. The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults. Clin Mol Hepatol. 2013;19:140-147. [PMID: 23837138 DOI: 10.3350/cmh.2013.19.2.140] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
317 Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes 2013;4:51-63. [PMID: 23772273 DOI: 10.4239/wjd.v4.i3.51] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 118] [Article Influence: 11.2] [Reference Citation Analysis]
318 Ucar F, Sezer S, Erdogan S, Akyol S, Armutcu F, Akyol O. The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis. Redox Rep. 2013;18:127-133. [PMID: 23743495 DOI: 10.1179/1351000213y.0000000050] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 8.6] [Reference Citation Analysis]
319 Rector RS, Morris EM, Ridenhour S, Meers GM, Hsu FF, Turk J, Ibdah JA. Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect. Hepatology 2013;57:2213-23. [PMID: 23359250 DOI: 10.1002/hep.26285] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
320 Montesi L, Moscatiello S, Malavolti M, Marzocchi R, Marchesini G. Physical activity for the prevention and treatment of metabolic disorders. Intern Emerg Med. 2013;8:655-666. [PMID: 23657989 DOI: 10.1007/s11739-013-0953-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
321 Li X, Choi Y, Yanakawa Y, Park T. Piperonal prevents high-fat diet-induced hepatic steatosis and insulin resistance in mice via activation of adiponectin/AMPK pathway. Int J Obes (Lond) 2014;38:140-7. [PMID: 23711775 DOI: 10.1038/ijo.2013.70] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
322 Angelico F, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews 2013. [DOI: 10.1002/14651858.cd005166.pub3] [Reference Citation Analysis]
323 Lin LJ, Cao N, Zheng CQ, Lin Y, Wang DX, Jin Y. An epidemiological survey of prevalence of fatty liver disease in a general adult population in Shenyang. Shijie Huaren Xiaohua Zazhi 2013; 21(12): 1114-1119 [DOI: 10.11569/wcjd.v21.i12.1114] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
324 Hsieh FC, Lee CL, Chai CY, Chen WT, Lu YC, Wu CS. Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. Nutr Metab (Lond) 2013;10:35. [PMID: 23590862 DOI: 10.1186/1743-7075-10-35] [Cited by in Crossref: 151] [Cited by in F6Publishing: 160] [Article Influence: 15.1] [Reference Citation Analysis]
325 Soresi M, Noto D, Cefalù AB, Martini S, Vigna GB, Fonda M, Manzato E, Cattin L, Fellin R, Averna MR, Notarbartolo A; Metabolic Syndrome Study Group. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetol 2013;50:241-9. [PMID: 22684314 DOI: 10.1007/s00592-012-0406-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
326 Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in non alcoholic fatty liver disease. World J Hepatol 2013; 5(3): 109-113 [PMID: 23556042 DOI: 10.4254/wjh.v5.i3.109] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 7.1] [Reference Citation Analysis]
327 Margariti A, Deutsch M, Manolakopoulos S, Tiniakos D, Papatheodoridis GV. The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2013;47:280-6. [PMID: 23391869 DOI: 10.1097/MCG.0b013e31826be328] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
328 Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013; 19(8): 1166-1172 [PMID: 23482247 DOI: 10.3748/wjg.v19.i8.1166] [Cited by in CrossRef: 151] [Cited by in F6Publishing: 158] [Article Influence: 15.1] [Reference Citation Analysis]
329 Zhou J, Mo Y, Li H, Ran X, Yang W, Li Q, Peng Y, Li Y, Gao X, Luan X, Wang W, Jia W. Alanine aminotransferase is associated with an adverse nocturnal blood glucose profile in individuals with normal glucose regulation. PLoS One 2013;8:e56072. [PMID: 23424646 DOI: 10.1371/journal.pone.0056072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
330 Dongiovanni P, Valenti L. Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility? PPAR Res. 2013;2013:452061. [PMID: 23431284 DOI: 10.1155/2013/452061] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
331 Huang SC, Yang YJ. Serum retinol-binding protein 4 is independently associated with pediatric NAFLD and fasting triglyceride level. J Pediatr Gastroenterol Nutr 2013;56:145-50. [PMID: 22983378 DOI: 10.1097/MPG.0b013e3182722aee] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
332 Saligram S, Williams EJ, Masding MG. Raised liver enzymes in newly diagnosed Type 2 diabetes are associated with weight and lipids, but not glycaemic control. Indian J Endocrinol Metab 2012;16:1012-4. [PMID: 23226654 DOI: 10.4103/2230-8210.103027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
333 Rahman S, Al-mahtab M, Jamshed Alam M. Association of Fatty Liver and Hypothyroidism. Euroasian Journal of Hepato-Gastroenterology 2013;3:8-9. [DOI: 10.5005/jp-journals-10018-1052] [Reference Citation Analysis]
334 Zhang Y, Baker SS, Baker RD, Zhu R, Zhu L. Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism. PLoS One 2012;7:e51131. [PMID: 23300535 DOI: 10.1371/journal.pone.0051131] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
335 Edwards CR, Hindle AK, Latham PS, Fu SW, Brody FJ. Resistin expression correlates with steatohepatitis in morbidly obese patients. Surg Endosc. 2013;27:1310-1314. [PMID: 23233000 DOI: 10.1007/s00464-012-2603-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
336 Silva LGDOE, Manso JEF, Silva RARND, Pereira SE, Saboya Sobrinho CJ, Rangel CW. Relação entre o estado nutricional de vitamina a e a regressão da esteatose hepática após gastroplastia em Y- de- Roux para tratamento da obesidade classe III. ABCD, arq bras cir dig 2012;25:250-6. [DOI: 10.1590/s0102-67202012000400008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
337 Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, Janssen HL. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol 2012;57:1305-11. [PMID: 22871499 DOI: 10.1016/j.jhep.2012.07.028] [Cited by in Crossref: 157] [Cited by in F6Publishing: 158] [Article Influence: 14.3] [Reference Citation Analysis]
338 Han J, Kim EH, Choi W, Jun HS. Glucose-responsive artificial promoter-mediated insulin gene transfer improves glucose control in diabetic mice. World J Gastroenterol 2012; 18(44): 6420-6426 [PMID: 23197887 DOI: 10.3748/wjg.v18.i44.6420] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
339 Tai CM, Huang CK, Hwang JC, Chiang H, Chang CY, Lee CT, Yu ML, Lin JT. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg. 2012;22:1016-1021. [PMID: 22161114 DOI: 10.1007/s11695-011-0579-7] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
340 Hadi NR, Al-Amran FG, Swadi A. Metformin ameliorates methotrexate-induced hepatotoxicity. J Pharmacol Pharmacother. 2012;3:248-253. [PMID: 23129960 DOI: 10.4103/0976-500x.99426] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
341 Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol 2012;57:1097-109. [PMID: 22659519 DOI: 10.1016/j.jhep.2012.04.041] [Cited by in Crossref: 148] [Cited by in F6Publishing: 150] [Article Influence: 13.5] [Reference Citation Analysis]
342 Zarrinpar A, Loomba R. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;36:909-21. [PMID: 23057494 DOI: 10.1111/apt.12084] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 6.9] [Reference Citation Analysis]
343 Anbalagan VP, Venkataraman V, Vamsi M, Deepa M, Mohan V. A simple Indian diabetes risk score could help identify nondiabetic individuals at high risk of non-alcoholic fatty liver disease (CURES-117). J Diabetes Sci Technol 2012;6:1429-35. [PMID: 23294790 DOI: 10.1177/193229681200600624] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
344 Notarnicola M, Misciagna G, Tutino V, Chiloiro M, Osella AR, Guerra V, Bonfiglio C, Caruso MG. Increased serum levels of lipogenic enzymes in patients with severe liver steatosis. Lipids Health Dis 2012;11:145. [PMID: 23110339 DOI: 10.1186/1476-511X-11-145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
345 Lo JC, Jamsai D, O'Connor AE, Borg C, Clark BJ, Whisstock JC, Field MC, Adams V, Ishikawa T, Aitken RJ, Whittle B, Goodnow CC, Ormandy CJ, O'Bryan MK. RAB-like 2 has an essential role in male fertility, sperm intra-flagellar transport, and tail assembly. PLoS Genet 2012;8:e1002969. [PMID: 23055941 DOI: 10.1371/journal.pgen.1002969] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 5.0] [Reference Citation Analysis]
346 Simental-Mendía LE, Rodríguez-Hernández H, Rodríguez-Morán M, Guerrero-Romero F. The alanine aminotransferase to triglycerides ratio as a marker to identify nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2012;24:1173-7. [PMID: 22735606 DOI: 10.1097/MEG.0b013e3283564ee5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
347 Ananiev J, Penkova M, Tchernev G, Gulubova M. Macrophages, TGF-β1 expression and iron deposition in development of NASH. Open Medicine 2012;7:599-603. [DOI: 10.2478/s11536-012-0033-9] [Reference Citation Analysis]
348 Kita Y, Takamura T, Misu H, Ota T, Kurita S, Takeshita Y, Uno M, Matsuzawa-Nagata N, Kato K, Ando H. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One. 2012;7:e43056. [PMID: 23028442 DOI: 10.1371/journal.pone.0043056] [Cited by in Crossref: 100] [Cited by in F6Publishing: 105] [Article Influence: 9.1] [Reference Citation Analysis]
349 Komshilova KA, Troshina EA, Butrova SA, Bogomolov PO, Knyazeva AP. Cardiometabolic risk factors in different clinicomorphological stages of non-alcoholic fatty liver disease in patients with abdominal obesity. Obes metabol 2012;9:20-25. [DOI: 10.14341/2071-8713-4968] [Reference Citation Analysis]
350 Shimizu M, Tanaka T, Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol. 2013;35:191-202. [PMID: 22945457 DOI: 10.1007/s00281-012-0336-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
351 Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012;56:943-51. [PMID: 22505194 DOI: 10.1002/hep.25772] [Cited by in Crossref: 322] [Cited by in F6Publishing: 300] [Article Influence: 29.3] [Reference Citation Analysis]
352 Xu L, Xu C, Yu C, Miao M, Zhang X, Zhu Z, Ding X, Li Y. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS One. 2012;7:e44136. [PMID: 22952901 DOI: 10.1371/journal.pone.0044136] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
353 Chon CW, Kim BS, Cho YK, Sung KC, Bae JC, Kim TW, Won HS, Joo KJ. Effect of nonalcoholic Fatty liver disease on the development of type 2 diabetes in nonobese, nondiabetic korean men. Gut Liver. 2012;6:368-373. [PMID: 22844567 DOI: 10.5009/gnl.2012.6.3.368] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
354 Kim B, Jung J, Kim D, Kim Y, Jeong I. Inhibitory Activity of Intracellular Lipid Accumulation by Various Marine Extracts in HepG2 Cells. Korean Journal of Food Science and Technology 2012;44:362-6. [DOI: 10.9721/kjfst.2012.44.3.362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
355 Agrawal S, Duseja AK. Non-alcoholic Fatty Liver Disease: East Versus West. J Clin Exp Hepatol 2012;2:122-34. [PMID: 25755421 DOI: 10.1016/S0973-6883(12)60101-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
356 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384-91. [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027] [Cited by in Crossref: 602] [Cited by in F6Publishing: 622] [Article Influence: 54.7] [Reference Citation Analysis]
357 Graff M, North KE, Franceschini N, Reiner AP, Feitosa M, Carr JJ, Gordon-Larsen P, Wojczynski MK, Borecki IB. PNPLA3 gene-by-visceral adipose tissue volume interaction and the pathogenesis of fatty liver disease: the NHLBI family heart study. Int J Obes (Lond) 2013;37:432-8. [PMID: 22546774 DOI: 10.1038/ijo.2012.65] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
358 Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2012;302:G762-72. [PMID: 22268099 DOI: 10.1152/ajpgi.00476.2011] [Cited by in Crossref: 171] [Cited by in F6Publishing: 178] [Article Influence: 15.5] [Reference Citation Analysis]
359 Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;56:944-51. [PMID: 22023985 DOI: 10.1016/j.jhep.2011.08.018] [Cited by in Crossref: 377] [Cited by in F6Publishing: 381] [Article Influence: 34.3] [Reference Citation Analysis]
360 Wang JK, Feng ZW, Li YC, Li QY, Tao XY. Association of tumor necrosis factor-α gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol 2012;27:670-6. [PMID: 22097889 DOI: 10.1111/j.1440-1746.2011.06978.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
361 Safi S, Hommadi A, Mouden K, Ajdi F, Hassikou H, Messayeh T, Baaj M, Nazzi M, Hadri L. Prévalences et caractéristiques générales des stéatopathies non alcooliques du foie chez les marocains diabétiques de type 2. Cahiers de Nutrition et de Diététique 2012;47:50-56. [DOI: 10.1016/j.cnd.2011.04.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
362 Berglund ED, Vianna CR, Donato J Jr, Kim MH, Chuang JC, Lee CE, Lauzon DA, Lin P, Brule LJ, Scott MM, Coppari R, Elmquist JK. Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin Invest 2012;122:1000-9. [PMID: 22326958 DOI: 10.1172/JCI59816] [Cited by in Crossref: 236] [Cited by in F6Publishing: 248] [Article Influence: 21.5] [Reference Citation Analysis]
363 Shi SY, Martin RG, Duncan RE, Choi D, Lu SY, Schroer SA, Cai EP, Luk CT, Hopperton KE, Domenichiello AF, Tang C, Naples M, Dekker MJ, Giacca A, Adeli K, Wagner KU, Bazinet RP, Woo M. Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. J Biol Chem 2012;287:10277-88. [PMID: 22275361 DOI: 10.1074/jbc.M111.317453] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
364 Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol 2012; 18(3): 237-243 [PMID: 22294826 DOI: 10.3748/wjg.v18.i3.237] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 94] [Article Influence: 7.9] [Reference Citation Analysis]
365 Lee WJ, Hur KY, Lakadawala M, Kasama K, Wong SK, Lee YC. Gastrointestinal metabolic surgery for the treatment of diabetic patients: a multi-institutional international study. J Gastrointest Surg 2012;16:45-51; discussion 51-2. [PMID: 22042564 DOI: 10.1007/s11605-011-1740-2] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 6.4] [Reference Citation Analysis]
366 Pitchumoni CS, Pitchumoni CS, Pitchumoni CS. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Geriatric Gastroenterology 2012. [DOI: 10.1007/978-1-4419-1623-5_40] [Reference Citation Analysis]
367 North KE, Graff M, Franceschini N, Reiner AP, Feitosa MF, Carr JJ, Gordon-Larsen P, Wojczynski MK, Borecki IB. Sex and race differences in the prevalence of fatty liver disease as measured by computed tomography liver attenuation in European American and African American participants of the NHLBI family heart study. Eur J Gastroenterol Hepatol 2012;24:9-16. [PMID: 21900826 DOI: 10.1097/MEG.0b013e32834a94fb] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
368 Barry CT, Mills B, Hah Z, Mooney RA, Ryan CK, Rubens DJ, Parker KJ. Shear wave dispersion measures liver steatosis. Ultrasound Med Biol 2012;38:175-82. [PMID: 22178165 DOI: 10.1016/j.ultrasmedbio.2011.10.019] [Cited by in Crossref: 104] [Cited by in F6Publishing: 80] [Article Influence: 8.7] [Reference Citation Analysis]
369 Caldwell SH, Argo CK, Al‐osaimi AMS. Nonalcoholic Fatty Liver Disease. Schiff's Diseases of the Liver 2011. [DOI: 10.1002/9781119950509.ch32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
370 Bulum T, Kolarić B, Duvnjak L, Duvnjak M. Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig Dis Sci 2011;56:3655-63. [PMID: 21735081 DOI: 10.1007/s10620-011-1807-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
371 Soverini V, Persico M, Bugianesi E, Forlani G, Salamone F, Masarone M, La Mura V, Mazzotti A, Bruno A, Marchesini G. HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. Acta Diabetol 2011;48:337-43. [PMID: 21574001 DOI: 10.1007/s00592-011-0293-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
372 Agrawal S, Daruwala C. Metabolic syndrome and hepatic resection: improving outcome. HPB (Oxford) 2011;13:846-59. [PMID: 22081919 DOI: 10.1111/j.1477-2574.2011.00380.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
373 Aljabri KS, Bokhari SA, Fageeh SM, Alharbi AM, Abaza MA. Glycogen hepatopathy in a 13-year-old male with type 1 diabetes. Ann Saudi Med. 2011;31:424-427. [PMID: 21727748 DOI: 10.4103/0256-4947.81803] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
374 Das UN. A defect in the activities of Δ6 and Δ5 desaturases and pro-resolution bioactive lipids in the pathobiology of non-alcoholic fatty liver disease. World J Diabetes 2011; 2(11): 176-188 [PMID: 22087354 DOI: 10.4239/wjd.v2.i11.176] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
375 Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2011;4:249-263. [PMID: 21765869 DOI: 10.1177/1756283x11403809] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 4.3] [Reference Citation Analysis]
376 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 126] [Cited by in F6Publishing: 150] [Article Influence: 10.5] [Reference Citation Analysis]
377 Xia MF, Yan HM, He WY, Li XM, Li CL, Yao XZ, Li RK, Zeng MS, Gao X. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring). 2012;20:444-452. [PMID: 22016092 DOI: 10.1038/oby.2011.302] [Cited by in Crossref: 96] [Cited by in F6Publishing: 102] [Article Influence: 8.0] [Reference Citation Analysis]
378 Rocha PM, Barata JT, Minderico CS, Silva AM, Teixeira PJ, Sardinha LB. Visceral abdominal and subfascial femoral adipose tissue have opposite associations with liver fat in overweight and obese premenopausal caucasian women. J Lipids 2011;2011:154672. [PMID: 21961071 DOI: 10.1155/2011/154672] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
379 Hatziagelaki E, Karageorgopoulos DE, Chounta A, Tsiavou A, Falagas ME, Dimitriadis G. Predictors of impaired glucose regulation in patients with non-alcoholic fatty liver disease. Exp Diabetes Res 2012;2012:351974. [PMID: 21960993 DOI: 10.1155/2012/351974] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
380 Uslusoy HS, Nak SG, Gülten M. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol 2011; 3(8): 219-227 [PMID: 21954411 DOI: 10.4254/wjh.v3.i8.219] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
381 Cahova M, Dankova H, Palenickova E, Papackova Z, Komers R, Zdychova J, Sticova E, Kazdova L. The increased activity of liver lysosomal lipase in nonalcoholic Fatty liver disease contributes to the development of hepatic insulin resistance. Biochem Res Int 2012;2012:135723. [PMID: 21904679 DOI: 10.1155/2012/135723] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
382 O’Brien J, Powell LW. Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int. 2012;6:332-341. [PMID: 22020821 DOI: 10.1007/s12072-011-9304-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
383 Hines CD, Frydrychowicz A, Hamilton G, Tudorascu DL, Vigen KK, Yu H, McKenzie CA, Sirlin CB, Brittain JH, Reeder SB. T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging. 2011;33:873-881. [PMID: 21448952 DOI: 10.1002/jmri.22514] [Cited by in Crossref: 164] [Cited by in F6Publishing: 167] [Article Influence: 13.7] [Reference Citation Analysis]
384 Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence. World J Gastroenterol 2011; 17(29): 3377-3389 [PMID: 21876630 DOI: 10.3748/wjg.v17.i29.3377] [Cited by in CrossRef: 179] [Cited by in F6Publishing: 195] [Article Influence: 14.9] [Reference Citation Analysis]
385 Lee K, Park J, Cho Y. Relationship Between Fatty Liver and Coronary Risk Factors among Health Examined Adult Women in an University Hospital. Journal of the Korea Academia-Industrial cooperation Society 2011;12:3130-3137. [DOI: 10.5762/kais.2011.12.7.3130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
386 Wang R, Lu Q, Feng J, Yin F, Qin C, Liu B, Liu Y, Liu X. Coexistence of non-alcoholic fatty liver disease with elevated alanine aminotransferase is associated with insulin resistance in young Han males. Endocrine. 2012;41:70-75. [PMID: 21796479 DOI: 10.1007/s12020-011-9511-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
387 Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L, Perseghin G. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011;54:145-52. [PMID: 21488080 DOI: 10.1002/hep.24356] [Cited by in Crossref: 168] [Cited by in F6Publishing: 156] [Article Influence: 14.0] [Reference Citation Analysis]
388 Aly FZ, Kleiner DE. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol 2011;18:294-300. [PMID: 21654360 DOI: 10.1097/PAP.0b013e318220f59b] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
389 Caldwell SH, Argo CK. Non-Alcoholic Fatty Liver Disease and Nutrition. Sherlock's Diseases of the Liver and Biliary System 2011. [DOI: 10.1002/9781444341294.ch28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
390 Manousou P, Kalambokis G, Grillo F, Watkins J, Xirouchakis E, Pleguezuelo M, Leandro G, Arvaniti V, Germani G, Patch D, Calvaruso V, Mikhailidis DP, Dhillon AP, Burroughs AK. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 2011;31:730-9. [PMID: 21457446 DOI: 10.1111/j.1478-3231.2011.02488.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 87] [Article Influence: 7.5] [Reference Citation Analysis]
391 Zhou L, Zhang W. Regulatory role of carbohydrate response element binding protein on hepatic glycolysis and lipogenesis. Academic Journal of Second Military Medical University 2011;31:318-322. [DOI: 10.3724/sp.j.1008.2011.00318] [Reference Citation Analysis]
392 Gentile CL, Frye M, Pagliassotti MJ. Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. Antioxid Redox Signal. 2011;15:505-521. [PMID: 21128705 DOI: 10.1089/ars.2010.3790] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 5.7] [Reference Citation Analysis]
393 Declercq V, Stringer D, Hunt R, Taylor CG, Zahradka P. Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae. Metabolic Syndrome 2011. [DOI: 10.1002/9780470910016.ch4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
394 Das SK, Balakrishnan V. Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease. Indian J Clin Biochem. 2011;26:202-209. [PMID: 22468051 DOI: 10.1007/s12291-011-0121-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
395 Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011;54:753-9. [PMID: 21126792 DOI: 10.1016/j.jhep.2010.07.040] [Cited by in Crossref: 136] [Cited by in F6Publishing: 137] [Article Influence: 11.3] [Reference Citation Analysis]
396 Schwingel PA, Cotrim HP, Salles BR, Almeida CE, dos Santos CR Jr, Nachef B, Andrade AR, Zoppi CC. Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease. Liver Int 2011;31:348-53. [PMID: 21040407 DOI: 10.1111/j.1478-3231.2010.02346.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
397 Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011;5:24-34. [PMID: 21660248 DOI: 10.2174/1874192401105010024] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
398 Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol. 2010;16:4784-4791. [PMID: 20939106 DOI: 10.3748/wjg.v16i38.4784] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
399 Barr J, Vázquez-Chantada M, Alonso C, Pérez-Cormenzana M, Mayo R, Galán A, Caballería J, Martín-Duce A, Tran A, Wagner C. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res. 2010;9:4501-4512. [PMID: 20684516 DOI: 10.1021/pr1002593] [Cited by in Crossref: 118] [Cited by in F6Publishing: 126] [Article Influence: 9.8] [Reference Citation Analysis]
400 Cadranel J. Elevación crónica de las transaminasas: hipertransaminasemia crónica. EMC - Tratado de Medicina 2011;15:1-8. [DOI: 10.1016/s1636-5410(11)71025-x] [Reference Citation Analysis]
401 Love-osborne K. Prediabetes and Type 2 Diabetes. Global Perspectives on Childhood Obesity 2011. [DOI: 10.1016/b978-0-12-374995-6.10009-x] [Reference Citation Analysis]
402 Raddatz D, Ramadori G. Hepatic Carbohydrate Metabolism. Molecular Pathology Library 2011. [DOI: 10.1007/978-1-4419-7107-4_8] [Reference Citation Analysis]
403 Castel H, Mathurin P. Stéatohépatite non alcoolique. EMC - Endocrinologie - Nutrition 2011;8:1-12. [DOI: 10.1016/s1155-1941(11)50624-9] [Reference Citation Analysis]
404 Lemoine M, Serfaty L. Foie métabolique. EMC - Hépatologie 2011;6:1-12. [DOI: 10.1016/s1155-1976(11)54601-7] [Reference Citation Analysis]
405 Joseph T, Naeger DM, Qayyum A. The obesity epidemic: The role of radiology. AR 2011. [DOI: 10.37549/ar1795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
406 Sundaram SS, Alonso EM. Abnormalities of Carbohydrate Metabolism and the Liver. Pediatric Gastrointestinal and Liver Disease 2011. [DOI: 10.1016/b978-1-4377-0774-8.10073-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
407 Cadranel J. Élévation chronique des transaminases : hypertransaminasémie chronique. EMC - Traité de médecine AKOS 2011;6:1-8. [DOI: 10.1016/s1634-6939(11)54649-6] [Reference Citation Analysis]
408 Patel R, Patel M, Tsai R, Lin V, Bookout AL, Zhang Y, Magomedova L, Li T, Chan JF, Budd C, Mangelsdorf DJ, Cummins CL. LXRβ is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J Clin Invest 2011;121:431-41. [PMID: 21123945 DOI: 10.1172/JCI41681] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 6.5] [Reference Citation Analysis]
409 Narciso-schiavon JL, Schiavon LDL, Carvalho-filho RJD, Hayashida DY, Wang JHJ, Souza TS, Emori CT, Ferraz MLG, Silva AEB. Clinical characteristics associated with hepatic steatosis on ultrasonography in patients with elevated alanine aminotransferase. Sao Paulo Med J 2010;128:342-7. [DOI: 10.1590/s1516-31802010000600006] [Reference Citation Analysis]
410 Jelinek D, Millward V, Birdi A, Trouard TP, Heidenreich RA, Garver WS. Npc1 haploinsufficiency promotes weight gain and metabolic features associated with insulin resistance. Hum Mol Genet 2011;20:312-21. [PMID: 21036943 DOI: 10.1093/hmg/ddq466] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
411 Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol 2010; 16(38): 4784-4791 [PMID: 20939106 DOI: 10.3748/wjg.v16.i38.4784] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 52] [Article Influence: 3.4] [Reference Citation Analysis]
412 Ichikawa K, Tagawa Y, Kawai M, Asamoto M, Shirai T. Promoting Effects of Streptozotocin-induced Diabetes on Induction of Hepatic Preneoplastic Lesions by Diethylnitrosamine in Rats. J Toxicol Pathol 2010;23:125-31. [PMID: 22272023 DOI: 10.1293/tox.23.125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
413 Mouralidarane A, Lin CI, Suleyman N, Soeda J, Oben JA. Practical management of the increasing burden of non-alcoholic fatty liver disease. Frontline Gastroenterol 2010;1:149-55. [PMID: 28839568 DOI: 10.1136/fg.2009.000935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
414 Daryani NE, Daryani NE, Alavian SM, Zare A, Fereshtehnejad SM, Keramati MR, Pashaei MR, Habibollahi P. Non-alcoholic steatohepatitis and influence of age and gender on histopathologic findings. World J Gastroenterol 2010; 16(33): 4169-4175 [PMID: 20806434 DOI: 10.3748/wjg.v16.i33.4169] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
415 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 711] [Cited by in F6Publishing: 738] [Article Influence: 54.7] [Reference Citation Analysis]
416 Barton JC, Edwards CQ, Phatak PD, Britton RS, Bacon BR. Insulin resistance and iron overload. Handbook of Iron Overload Disorders 2010. [DOI: 10.1017/cbo9780511777035.008] [Reference Citation Analysis]
417 Kirovski G, Schacherer D, Wobser H, Huber H, Niessen C, Beer C, Schölmerich J, Hellerbrand C. Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics. Int J Clin Exp Med. 2010;3:202-210. [PMID: 20827318 DOI: 10.1055/s-0029-1246560] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
418 Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010;105:1567-73. [PMID: 20145609 DOI: 10.1038/ajg.2010.18] [Cited by in Crossref: 197] [Cited by in F6Publishing: 206] [Article Influence: 15.2] [Reference Citation Analysis]
419 Basaranoglu M, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O, Sonsuz A. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(18): 2223-2226 [PMID: 20458758 DOI: 10.3748/wjg.v16.i18.2223] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
420 Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010;7:251-64. [PMID: 20368739 DOI: 10.1038/nrgastro.2010.41] [Cited by in Crossref: 493] [Cited by in F6Publishing: 503] [Article Influence: 37.9] [Reference Citation Analysis]
421 Massarweh NN, Park JO, Farjah F, Yeung RS, Symons RG, Vaughan TL, Baldwin LM, Flum DR. Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg. 2010;210:441-448. [PMID: 20347736 DOI: 10.1016/j.jamcollsurg.2009.12.026] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
422 Ercin CN, Dogru T, Tapan S, Karslioglu Y, Haymana C, Kilic S, Sonmez A, Yesilova Z, Uygun A, Gulsen M, Bagci S, Kemal Erbil M. Levels of soluble CD40 ligand and P-Selectin in nonalcoholic fatty liver disease. Dig Dis Sci 2010;55:1128-34. [PMID: 19440836 DOI: 10.1007/s10620-009-0817-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
423 Kirpich IA, Gobejishvili LN, Bon Homme M, Waigel S, Cave M, Arteel G, Barve SS, McClain CJ, Deaciuc IV. Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J Nutr Biochem 2011;22:38-45. [PMID: 20303728 DOI: 10.1016/j.jnutbio.2009.11.009] [Cited by in Crossref: 116] [Cited by in F6Publishing: 107] [Article Influence: 8.9] [Reference Citation Analysis]
424 Lebensztejn DM, Wojtkowska M, Skiba E, Werpachowska I, Tobolczyk J, Kaczmarski M. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease. Adv Med Sci 2009;54:177-82. [PMID: 20022856 DOI: 10.2478/v10039-009-0047-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
425 Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010;138:905-12. [PMID: 19931264 DOI: 10.1053/j.gastro.2009.11.013] [Cited by in Crossref: 195] [Cited by in F6Publishing: 208] [Article Influence: 15.0] [Reference Citation Analysis]
426 Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, Edelstein SL, Knowler WC; Diabetes Prevention Program Research Group. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 2010;18:1762-7. [PMID: 20186137 DOI: 10.1038/oby.2010.21] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
427 Hart CL, Batty GD, Morrison DS, Mitchell RJ, Smith GD. Obesity, overweight and liver disease in the Midspan prospective cohort studies. Int J Obes (Lond) 2010;34:1051-9. [PMID: 20142829 DOI: 10.1038/ijo.2010.20] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
428 Hines CD, Yu H, Shimakawa A, McKenzie CA, Warner TF, Brittain JH, Reeder SB. Quantification of hepatic steatosis with 3-T MR imaging: validation in ob/ob mice. Radiology 2010;254:119-28. [PMID: 20032146 DOI: 10.1148/radiol.09090131] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 5.2] [Reference Citation Analysis]
429 Finucane FM, Sharp SJ, Purslow LR, Horton K, Horton J, Savage DB, Brage S, Besson H, De Lucia Rolfe E, Sleigh A. The effects of aerobic exercise on metabolic risk, insulin sensitivity and intrahepatic lipid in healthy older people from the Hertfordshire Cohort Study: a randomised controlled trial. Diabetologia. 2010;53:624-631. [PMID: 20052455 DOI: 10.1007/s00125-009-1641-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
430 Lanthier N, Molendi-Coste O, Horsmans Y, van Rooijen N, Cani PD, Leclercq IA. Kupffer cell activation is a causal factor for hepatic insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010;298:G107-16. [PMID: 19875703 DOI: 10.1152/ajpgi.00391.2009] [Cited by in Crossref: 172] [Cited by in F6Publishing: 177] [Article Influence: 13.2] [Reference Citation Analysis]
431 Oster H. Circadian Clocks and Metabolism. The Circadian Clock 2010. [DOI: 10.1007/978-1-4419-1262-6_5] [Reference Citation Analysis]
432 Kelishadi R, Cook SR, Adibi A, Faghihimani Z, Ghatrehsamani S, Beihaghi A, Salehi H, Khavarian N, Poursafa P. Association of the components of the metabolic syndrome with non-alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents. Diabetol Metab Syndr 2009;1:29. [PMID: 20028551 DOI: 10.1186/1758-5996-1-29] [Cited by in Crossref: 51] [Cited by in F6Publishing: 61] [Article Influence: 3.6] [Reference Citation Analysis]
433 Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009;15:1814-20. [PMID: 19938128 DOI: 10.1002/lt.21927] [Cited by in Crossref: 135] [Cited by in F6Publishing: 122] [Article Influence: 9.6] [Reference Citation Analysis]
434 Kamada Y, Nakamura T, Funahashi T, Ryo M, Nishizawa H, Okauchi Y, Fukushima J, Yoshida Y, Kiso S, Shimomura I, Hayashi N. Visceral obesity and hypoadiponectinemia are significant determinants of hepatic dysfunction: An epidemiologic study of 3827 Japanese subjects. J Clin Gastroenterol 2009;43:995-1000. [PMID: 19407661 DOI: 10.1097/MCG.0b013e3181962de8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
435 Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009;13:631-47. [PMID: 19818310 DOI: 10.1016/j.cld.2009.07.007] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 6.5] [Reference Citation Analysis]
436 Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr 2009;21:529-35. [PMID: 19444112 DOI: 10.1097/MOP.0b013e32832cb16f] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 4.3] [Reference Citation Analysis]
437 Farrell GC. The liver and the waistline: Fifty years of growth. J Gastroenterol Hepatol 2009;24 Suppl 3:S105-18. [PMID: 19799688 DOI: 10.1111/j.1440-1746.2009.06080.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
438 Graham RC, Burke A, Stettler N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J Pediatr Gastroenterol Nutr 2009;49:442-9. [PMID: 19644391 DOI: 10.1097/MPG.0b013e31819f73b4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
439 Enns LC, Morton JF, Mangalindan RS, McKnight GS, Schwartz MW, Kaeberlein MR, Kennedy BK, Rabinovitch PS, Ladiges WC. Attenuation of age-related metabolic dysfunction in mice with a targeted disruption of the Cbeta subunit of protein kinase A. J Gerontol A Biol Sci Med Sci 2009;64:1221-31. [PMID: 19776218 DOI: 10.1093/gerona/glp133] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
440 Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2010;31:62-70. [PMID: 19761871 DOI: 10.1016/j.cct.2009.09.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
441 Kathirvel E, Morgan K, French SW, Morgan TR. Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009;21:973-83. [PMID: 19307976 DOI: 10.1097/MEG.0b013e328328f461] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
442 Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009;41:615-25. [PMID: 19223251 DOI: 10.1016/j.dld.2009.01.004] [Cited by in Crossref: 188] [Cited by in F6Publishing: 192] [Article Influence: 13.4] [Reference Citation Analysis]
443 Ratziu V, Poynard T. Stéatohépatite métabolique : 30 ans de recherches qui ont changé la NASH. Gastroentérologie Clinique et Biologique 2009;33:850-858. [DOI: 10.1016/j.gcb.2009.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
444 Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009;51:380-8. [PMID: 19501927 DOI: 10.1016/j.jhep.2009.03.025] [Cited by in Crossref: 216] [Cited by in F6Publishing: 215] [Article Influence: 15.4] [Reference Citation Analysis]
445 Ohuchi H, Miyamoto Y, Yamamoto M, Ishihara H, Takata H, Miyazaki A, Yamada O, Yagihara T. High prevalence of abnormal glucose metabolism in young adult patients with complex congenital heart disease. Am Heart J 2009;158:30-9. [PMID: 19540389 DOI: 10.1016/j.ahj.2009.04.021] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
446 Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009;46:113-8. [PMID: 18839053 DOI: 10.1007/s00592-008-0067-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 4.5] [Reference Citation Analysis]
447 Rook M, Rosenthal P. Caring for adults with pediatric liver disease. Curr Gastroenterol Rep. 2009;11:83-89. [PMID: 19166664 DOI: 10.1007/s11894-009-0013-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
448 Ahsan MK, Okuyama H, Hoshino Y, Oka S, Masutani H, Yodoi J, Nakamura H. Thioredoxin-binding Protein-2 Deficiency Enhances Methionine-Choline Deficient Diet-induced Hepatic Steatosis but Inhibits Steatohepatitis in Mice. Antioxidants & Redox Signaling 2011. [DOI: 10.1089/ars.2008.2385] [Reference Citation Analysis]
449 Smith B, George J. Adipocyte-hepatocyte crosstalk and the pathogenesis of nonalcoholic fatty liver disease. Hepatology 2009;49:1765-7. [PMID: 19402105 DOI: 10.1002/hep.22937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
450 Uslusoy HS, Nak SG, Gülten M, Bıyıklı Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol 2009; 15(15): 1863-1868 [PMID: 19370784 DOI: 10.3748/wjg.15.1863] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
451 Lee JS, Kim SH, Jun DW, Han JH, Jang EC, Park JY, Son BK, Kim SH, Jo YJ, Park YS, Kim YS. Clinical implications of fatty pancreas: Correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol 2009; 15(15): 1869-1875 [PMID: 19370785 DOI: 10.3748/wjg.15.1869] [Cited by in CrossRef: 170] [Cited by in F6Publishing: 179] [Article Influence: 12.1] [Reference Citation Analysis]
452 Li S, Chen X, Zhang H, Liang X, Xiang Y, Yu C, Zen K, Li Y, Zhang CY. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res. 2009;50:1756-1765. [PMID: 19372595 DOI: 10.1194/jlr.m800509-jlr200;] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
453 Li S, Chen X, Zhang H, Liang X, Xiang Y, Yu C, Zen K, Li Y, Zhang CY. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res. 2009;50:1756-1765. [PMID: 19372595 DOI: 10.1194/jlr.m800509-jlr200] [Cited by in Crossref: 147] [Cited by in F6Publishing: 161] [Article Influence: 10.5] [Reference Citation Analysis]
454 Yun JW, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI. Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int 2009;29:525-9. [PMID: 19323780 DOI: 10.1111/j.1478-3231.2008.01920.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
455 Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009;50:797-804. [PMID: 19231016 DOI: 10.1016/j.jhep.2008.11.017] [Cited by in Crossref: 102] [Cited by in F6Publishing: 109] [Article Influence: 7.3] [Reference Citation Analysis]
456 Pardina E, Baena-Fustegueras JA, Llamas R, Catalán R, Galard R, Lecube A, Fort JM, Llobera M, Allende H, Vargas V. Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis. Obes Surg. 2009;19:608-616. [PMID: 19301078 DOI: 10.1007/s11695-009-9827-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
457 Uslusoy HS, Nak SG, Gülten M, Bıyıklı Z. Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases. World J Gastroenterol 2009; 15(9): 1093-1098 [PMID: 19266602 DOI: 10.3748/wjg.15.1093] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
458 Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009;49:791-801. [PMID: 19105205 DOI: 10.1002/hep.22726] [Cited by in Crossref: 263] [Cited by in F6Publishing: 256] [Article Influence: 18.8] [Reference Citation Analysis]
459 Sundaram SS, Nadeau K. Nonalcoholic Fatty Liver Disease in Pediatric Patients. Obesity Management 2009;5:65-71. [DOI: 10.1089/obe.2009.0206] [Reference Citation Analysis]
460 Verrotti A, Di Marco G, la Torre R, Pelliccia P, Chiarelli F. Nonalcoholic fatty liver disease during valproate therapy. Eur J Pediatr. 2009;168:1391-1394. [PMID: 19184102 DOI: 10.1007/s00431-009-0927-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
461 Rocha R, Cotrim HP, Bitencourt AG, Barbosa DB, Santos AS, Almeida Ade M, Cunha B, Guimarães I. Nonalcoholic fatty liver disease in asymptomatic Brazilian adolescents. World J Gastroenterol 2009;15:473-7. [PMID: 19152453 DOI: 10.3748/wjg.15.473] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
462 Gaiani S, Avogaro A, Bombonato GC, Bolognesi M, Amor F, Vigili de Kreutzenberg S, Guarneri G, Sacerdoti DF. Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: prevalence and relationships with hemodynamic alterations detected with doppler sonography. J Ultrasound. 2009;12:1-5. [PMID: 23396636 DOI: 10.1016/j.jus.2008.12.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
463 Fu C, Chen M, Li Y, Liu T, Wang L. The Risk Factors for Ultrasound-diagnosed Non-alcoholic Fatty Liver Disease Among Adolescents. Ann Acad Med Singap 2009;38:15-21. [DOI: 10.47102/annals-acadmedsg.v38n1p15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
464 Chang CY, Whitt K, Liu Z, Caldwell SH. The Liver and Insulin Resistance: The Important Convergence of Endocrinology and Hepatology. Insulin Resistance. [DOI: 10.1007/978-1-59745-192-5_13] [Reference Citation Analysis]
465 Choi A, Park S, Kim S, Cho B. Research Related to Chronic Kidney Disease in BMI >25 Overweight Children. J Korean Soc Pediatr Nephrol 2009;13:75. [DOI: 10.3339/jkspn.2009.13.1.75] [Reference Citation Analysis]
466 Stewart KJ. Exercise, Adiposity, and Regional Fat Distribution. Diabetes and Exercise 2009. [DOI: 10.1007/978-1-59745-260-1_7] [Reference Citation Analysis]
467 George J, van der Poorten D. State-of-the-Art Lecture: Non-alcoholic steatohepatitis: concepts on pathogenesis and therapy. Chronic Inflammation of Liver and Gut 2009. [DOI: 10.1007/978-1-4020-9353-1_15] [Reference Citation Analysis]
468 Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009;44:1236-43. [PMID: 19670076 DOI: 10.1080/00365520903171284] [Cited by in Crossref: 140] [Cited by in F6Publishing: 116] [Article Influence: 10.0] [Reference Citation Analysis]
469 Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008;8:301-309. [PMID: 18840360 DOI: 10.1016/j.cmet.2008.08.015] [Cited by in Crossref: 599] [Cited by in F6Publishing: 627] [Article Influence: 39.9] [Reference Citation Analysis]
470 Sazci A, Akpinar G, Aygun C, Ergul E, Senturk O, Hulagu S. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig Dis Sci 2008;53:3218-24. [PMID: 18465245 DOI: 10.1007/s10620-008-0271-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
471 Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Kumada H. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol 2008;23:1739-46. [PMID: 18713301 DOI: 10.1111/j.1440-1746.2008.05436.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
472 Brudevold R, Hole T, Hammerstrøm J. Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload. PLoS One. 2008;3:e3547. [PMID: 18958176 DOI: 10.1371/journal.pone.0003547] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
473 Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, Wakkach A, Dahman M, Tordjman J, Clément K, McQuaid SE, Frayn KN, Huet PM, Gugenheim J, Lotersztajn S, Le Marchand-Brustel Y, Tran A, Gual P. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 2009;58:125-33. [PMID: 18952835 DOI: 10.2337/db08-0400] [Cited by in Crossref: 104] [Cited by in F6Publishing: 113] [Article Influence: 6.9] [Reference Citation Analysis]
474 Nannipieri M, Cecchetti F, Anselmino M, Mancini E, Marchetti G, Bonotti A, Baldi S, Solito B, Giannetti M, Pinchera A. Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes Surg. 2009;19:467-474. [PMID: 18923878 DOI: 10.1007/s11695-008-9701-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
475 Deivanayagam S, Mohammed BS, Vitola BE, Naguib GH, Keshen TH, Kirk EP, Klein S. Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. Am J Clin Nutr 2008;88:257-62. [PMID: 18689359 DOI: 10.1093/ajcn/88.2.257] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 5.6] [Reference Citation Analysis]
476 Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009;30:88-96. [PMID: 18804555 DOI: 10.1016/j.cct.2008.09.00] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
477 Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009;30:88-96. [PMID: 18804555 DOI: 10.1016/j.cct.2008.09.003] [Cited by in Crossref: 114] [Cited by in F6Publishing: 106] [Article Influence: 7.6] [Reference Citation Analysis]
478 Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;28:503-22. [PMID: 18532991 DOI: 10.1111/j.1365-2036.2008.03752.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 5.0] [Reference Citation Analysis]
479 Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008;6:87-102. [PMID: 18510434 DOI: 10.1089/met.2007.0029] [Cited by in Crossref: 178] [Cited by in F6Publishing: 187] [Article Influence: 11.9] [Reference Citation Analysis]
480 Shimizu Y. Liver in systemic disease. World J Gastroenterol 2008; 14(26): 4111-4119 [PMID: 18636653 DOI: 10.3748/wjg.14.4111] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 48] [Article Influence: 2.7] [Reference Citation Analysis]
481 El-Zayadi AR. Hepatic steatosis: A benign disease or a silent killer. World J Gastroenterol 2008; 14(26): 4120-4126 [PMID: 18636654 DOI: 10.3748/wjg.14.4120] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 56] [Article Influence: 3.8] [Reference Citation Analysis]
482 Watanabe K, Ohnishi S, Manabe I, Nagai R, Kadowaki T. KLF6 in nonalcoholic fatty liver disease: role of fibrogenesis and carcinogenesis. Gastroenterology 2008;135:309-12. [PMID: 18558090 DOI: 10.1053/j.gastro.2008.06.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
483 Roldan-Valadez E, Favila R, Martínez-López M, Uribe M, Méndez-Sánchez N. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol 2008;7:212-20. [PMID: 18753987] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 5.3] [Reference Citation Analysis]
484 Kim CH, Kallman JB, Bai C, Pawloski L, Gewa C, Arsalla A, Sabatella ME, Younossi ZM. Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes Surg. 2010;20:154-160. [PMID: 18560947 DOI: 10.1007/s11695-008-9549-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
485 Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, Hsu CL, Ma WL, Jokinen J, Sparks JD, Yeh S, Chang C. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology 2008;47:1924-35. [PMID: 18449947 DOI: 10.1002/hep.22252] [Cited by in Crossref: 143] [Cited by in F6Publishing: 142] [Article Influence: 9.5] [Reference Citation Analysis]
486 Kechagias S, Ernersson A, Dahlqvist O, Lundberg P, Lindström T, Nystrom FH; Fast Food Study Group. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 2008;57:649-54. [PMID: 18276725 DOI: 10.1136/gut.2007.131797] [Cited by in Crossref: 142] [Cited by in F6Publishing: 141] [Article Influence: 9.5] [Reference Citation Analysis]
487 Diehl AM, Choi SS. The Liver in Type 2 Diabetes Mellitus. Type 2 Diabetes Mellitus. [DOI: 10.1007/978-1-60327-043-4_21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
488 Swierczynski J, Sledzinski T, Slominska E, Smolenski R, Sledzinski Z. Serum phenylalanine concentration as a marker of liver function in obese patients before and after bariatric surgery. Obes Surg. 2009;19:883-889. [PMID: 18431611 DOI: 10.1007/s11695-008-9521-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
489 Stanhope KL, Havel PJ. Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. Curr Opin Lipidol 2008;19:16-24. [PMID: 18196982 DOI: 10.1097/MOL.0b013e3282f2b24a] [Cited by in Crossref: 184] [Cited by in F6Publishing: 157] [Article Influence: 12.3] [Reference Citation Analysis]
490 Krasnoff JB, Painter PL, Wallace JP, Bass NM, Merriman RB. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2008;47:1158-66. [PMID: 18266250 DOI: 10.1002/hep.22137] [Cited by in Crossref: 111] [Cited by in F6Publishing: 96] [Article Influence: 7.4] [Reference Citation Analysis]
491 Aller R, de Luis DA, Fernandez L, Calle F, Velayos B, Olcoz JL, Izaola O, Sagrado MG, Conde R, Gonzalez JM. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dis Sci 2008;53:1088-92. [PMID: 17934820 DOI: 10.1007/s10620-007-9981-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
492 Fong HF, Divasta AD, Difabio D, Ringelheim J, Jonas MM, Gordon CM. Prevalence and predictors of abnormal liver enzymes in young women with anorexia nervosa. J Pediatr 2008;153:247-53. [PMID: 18534220 DOI: 10.1016/j.jpeds.2008.01.036] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
493 Almeida AM, Cotrim HP, Barbosa DBV, Athayde LGM, Santos AS, Bitencourt AGV, Freitas LAR, Rios A, Alves E. Fatty liver disease in severe obese patients: Diagnostic value of abdominal ultrasound. World J Gastroenterol 2008; 14(9): 1415-1418 [PMID: 18322958 DOI: 10.3748/wjg.14.1415] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 83] [Article Influence: 5.1] [Reference Citation Analysis]
494 Love-Osborne KA, Nadeau KJ, Sheeder J, Fenton LZ, Zeitler P. Presence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease. J Adolesc Health 2008;42:543-8. [PMID: 18486862 DOI: 10.1016/j.jadohealth.2007.11.136] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
495 Valenti L, Dongiovanni P, Fracanzani AL, Fargion S. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations: response to Equitani et al. Diabetes Care 2008;31:e18; author reply e19. [PMID: 18308681 DOI: 10.2337/dc07-2181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
496 Lee TH, Kim WR, Benson JT, Therneau TM, Melton LJ 3rd. Serum aminotransferase activity and mortality risk in a United States community. Hepatology 2008;47:880-7. [PMID: 18302294 DOI: 10.1002/hep.22090] [Cited by in Crossref: 128] [Cited by in F6Publishing: 110] [Article Influence: 8.5] [Reference Citation Analysis]
497 Browning LM, Krebs JD, Siervo M, Hall RM, Finer N, Allison ME, Jebb SA. Inflammation is associated with liver function markers, independent of other metabolic risk factors in overweight women. Diabetes & Vascular Disease 2008;8:73-76. [DOI: 10.1177/14746514080080020401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
498 Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008;172:738-747. [PMID: 18245813 DOI: 10.2353/ajpath.2008.070097] [Cited by in Crossref: 119] [Cited by in F6Publishing: 126] [Article Influence: 7.9] [Reference Citation Analysis]
499 Song Z, Song M, Lee DY, Liu Y, Deaciuc IV, McClain CJ. Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation. Basic Clin Pharmacol Toxicol. 2007;101:262-268. [PMID: 17845508 DOI: 10.1111/j.1742-7843.2007.00116.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
500 Consequences of the Metabolic Syndrome. The Metabolic Syndrome in Clinical Practice 2008. [DOI: 10.1007/978-1-84628-911-8_5] [Reference Citation Analysis]
501 Adams L. Nonalcoholic Fatty Liver Disease and Diabetes Mellitus. Type 2 Diabetes 2007. [DOI: 10.3109/9780849379581-38] [Reference Citation Analysis]
502 Wang CH, Leung CH, Liu SC, Chung CH. Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease. J Formos Med Assoc 2006;105:743-52. [PMID: 16959622 DOI: 10.1016/S0929-6646(09)60202-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
503 MacDonald ML, Singaraja RR, Bissada N, Ruddle P, Watts R, Karasinska JM, Gibson WT, Fievet C, Vance JE, Staels B, Hayden MR. Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. J Lipid Res 2008;49:217-29. [PMID: 17960025 DOI: 10.1194/jlr.M700478-JLR200] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
504 Hussein O, Grosovski M, Schlesinger S, Szvalb S, Assy N. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci 2007;52:2512-9. [PMID: 17404856 DOI: 10.1007/s10620-006-9631-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
505 Degertekin B, Ozenirler S, Elbeg S, Akyol G. The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci 2007;52:2622-8. [PMID: 17429733 DOI: 10.1007/s10620-006-9147-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
506 Benini F, Pigozzi MG, Baisini O, Romanini L, Ahmed H, Pozzi A, Ricci C, Lanzini A. Increased serum gamma-glutamyl-transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C. J Gastroenterol Hepatol 2007;22:1621-6. [PMID: 17845689 DOI: 10.1111/j.1440-1746.2006.04733.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
507 Duvnjak M, Lerotić I, Baršić N, Tomašić V, Jukić LV, Velagić V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13(34): 4539-4550 [PMID: 17729403 DOI: 10.3748/wjg.v13.i34.4539] [Cited by in CrossRef: 166] [Cited by in F6Publishing: 183] [Article Influence: 10.4] [Reference Citation Analysis]
508 Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, Yueh SK. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 2007;22:1482-9. [PMID: 17716352 DOI: 10.1111/j.1440-1746.2006.04615.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 5.6] [Reference Citation Analysis]
509 Cree MG, Newcomer BR, Read LK, Sheffield-Moore M, Paddon-Jones D, Chinkes D, Aarsland A, Wolfe RR. Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment. Mech Ageing Dev 2007;128:558-65. [PMID: 17904198 DOI: 10.1016/j.mad.2007.08.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
510 Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007;133:496-506. [PMID: 17681171 DOI: 10.1053/j.gastro.2007.04.068] [Cited by in Crossref: 403] [Cited by in F6Publishing: 411] [Article Influence: 25.2] [Reference Citation Analysis]
511 Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007;47:239-44. [PMID: 17400323 DOI: 10.1016/j.jhep.2007.02.007] [Cited by in Crossref: 190] [Cited by in F6Publishing: 198] [Article Influence: 11.9] [Reference Citation Analysis]
512 van der Poorten D, George J. Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatol Int 2007;1:343-54. [PMID: 19669329 DOI: 10.1007/s12072-007-9011-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
513 Sobhonslidsuk A, Jongjirasiri S, Thakkinstian A, Wisedopas N, Bunnag P, Puavilai G. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. World J Gastroenterol 2007; 13(26): 3614-3618 [DOI: 10.3748/wjg.v13.i26.3614] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
514 Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13(26): 3540-3553 [PMID: 17659704 DOI: 10.3748/wjg.v13.i26.3540] [Cited by in CrossRef: 177] [Cited by in F6Publishing: 183] [Article Influence: 11.1] [Reference Citation Analysis]
515 Butrova SA, Eliseeva AY. Nealkogol'naya zhirovaya bolezn' pecheni: aktual'nye proekty. Obes metabol 2007;4:2-7. [DOI: 10.14341/2071-8713-5155] [Reference Citation Analysis]
516 Boden G. Pioglitazone and Nonalcoholic Steatohepatitis. Curr Diab Rep 2007;7:221-222. [DOI: 10.1007/s11892-007-0034-2] [Reference Citation Analysis]
517 Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A; Asia-Pacific Working Party for NAFLD. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol 2007;22:794-800. [PMID: 17498218 DOI: 10.1111/j.1440-1746.2007.04952.x] [Cited by in Crossref: 182] [Cited by in F6Publishing: 181] [Article Influence: 11.4] [Reference Citation Analysis]
518 Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102:1251-8. [PMID: 17391316 DOI: 10.1111/j.1572-0241.2007.01192.x] [Cited by in Crossref: 223] [Cited by in F6Publishing: 224] [Article Influence: 13.9] [Reference Citation Analysis]
519 Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007;132:2191-207. [PMID: 17498512 DOI: 10.1053/j.gastro.2007.03.055] [Cited by in Crossref: 234] [Cited by in F6Publishing: 252] [Article Influence: 14.6] [Reference Citation Analysis]
520 García-galiano D, Sánchez-garrido MA, Espejo I, Montero JL, Costán G, Marchal T, Membrives A, Gallardo-valverde JM, Muñoz-castañeda JR, Arévalo E, De la Mata M, Muntané J. IL-6 and IGF-1 are Independent Prognostic Factors of Liver Steatosis and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients. OBES SURG 2007;17:493-503. [DOI: 10.1007/s11695-007-9087-1] [Cited by in Crossref: 76] [Cited by in F6Publishing: 86] [Article Influence: 4.8] [Reference Citation Analysis]
521 Sakurai M, Takamura T, Ota T, Ando H, Akahori H, Kaji K, Sasaki M, Nakanuma Y, Miura K, Kaneko S. Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease. J Gastroenterol. 2007;42:312-317. [PMID: 17464461 DOI: 10.1007/s00535-006-1948-] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
522 Liang RJ, Wang HH, Lee WJ, Liew PL, Lin JT, Wu MS. Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg. 2007;17:45-56. [PMID: 17355768 DOI: 10.1007/s11695-007-9005-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
523 Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 2007;22:491-7. [PMID: 17376039 DOI: 10.1111/j.1440-1746.2006.04758.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 4.3] [Reference Citation Analysis]
524 Giannini EG, Savarino V. Predictors of pathological severity in non-alcoholic fatty liver disease: is East meeting West in the middle? J Gastroenterol Hepatol 2007;22:461-3. [PMID: 17376033 DOI: 10.1111/j.1440-1746.2007.04932.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
525 Pacifico L, Celestre M, Anania C, Paolantonio P, Chiesa C, Laghi A. MRI and ultrasound for hepatic fat quantification:relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr 2007;96:542-7. [PMID: 17306008 DOI: 10.1111/j.1651-2227.2007.00186.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 100] [Article Influence: 5.9] [Reference Citation Analysis]
526 Rubio A, Guruceaga E, Vázquez-Chantada M, Sandoval J, Martínez-Cruz LA, Segura V, Sevilla JL, Podhorski A, Corrales FJ, Torres L, Rodríguez M, Aillet F, Ariz U, Arrieta FM, Caballería J, Martín-Duce A, Lu SC, Martínez-Chantar ML, Mato JM. Identification of a gene-pathway associated with non-alcoholic steatohepatitis. J Hepatol 2007;46:708-18. [PMID: 17275126 DOI: 10.1016/j.jhep.2006.10.021] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
527 Ahmed MH, Byrne CD. Treating non-alcoholic fatty liver disease. Practice Nursing 2007;18:120-6. [DOI: 10.12968/pnur.2007.18.3.23284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
528 Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R, Imanaka M, Nishizawa H, Takahashi M, Seo Y, Hayashi Y, Kondo T, Okimura Y, Kaji H, Kitazawa R, Kitazawa S, Chihara K. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 2007;132:938-43. [PMID: 17324404 DOI: 10.1053/j.gastro.2006.12.024] [Cited by in Crossref: 114] [Cited by in F6Publishing: 122] [Article Influence: 7.1] [Reference Citation Analysis]
529 Kolwankar D, Vuppalanchi R, Ethell B, Jones DR, Wrighton SA, Hall SD, Chalasani N. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol 2007;5:388-93. [PMID: 17368239 DOI: 10.1016/j.cgh.2006.12.021] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 3.9] [Reference Citation Analysis]
530 Malik A, Cheah PL, Hilmi IN, Chan SP, Goh KL. Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. J Dig Dis 2007;8:58-64. [PMID: 17261137 DOI: 10.1111/j.1443-9573.2007.00286.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
531 Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis 2007;11:105-17, ix. [PMID: 17544974 DOI: 10.1016/j.cld.2007.02.013] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 5.6] [Reference Citation Analysis]
532 Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007;11:75-104, ix. [PMID: 17544973 DOI: 10.1016/j.cld.2007.02.011] [Cited by in Crossref: 114] [Cited by in F6Publishing: 126] [Article Influence: 7.1] [Reference Citation Analysis]
533 Moreno-torres A, Domingo P, Pujol J, Blanco-vaca F, Arroyo JA, Sambeat MA. Liver Triglyceride Content in HIV-1-Infected Patients on Combination Antiretroviral Therapy Studied with 1H-MR Spectroscopy. Antiviral Therapy 2007;12:195-204. [DOI: 10.1177/135965350701200203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
534 Kim HC, Choi KS, Jang YH, Shin HW, Kim DJ. Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys. Yonsei Med J 2006;47:542-50. [PMID: 16941745 DOI: 10.3349/ymj.2006.47.4.542] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
535 Çetinkaya A, Kantarçeken B, Büyükbeşe MA, Çelik M, Tolun Fİ. SERUM HOMOCYSTEINE LEVELS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. ELECTRON J GEN MED 2007;4:19-24. [DOI: 10.29333/ejgm/82416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
536 Futterweit W. Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. Insulin Resistance and Polycystic Ovarian Syndrome 2007. [DOI: 10.1007/978-1-59745-310-3_23] [Reference Citation Analysis]
537 Ito M, Suzuki J, Tsujioka S, Sasaki M, Gomori A, Shirakura T, Hirose H, Ito M, Ishihara A, Iwaasa H, Kanatani A. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res 2007;37:50-7. [PMID: 17300698 DOI: 10.1111/j.1872-034X.2007.00008.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 141] [Article Influence: 9.3] [Reference Citation Analysis]
538 Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, Akahori H, Misu H, Sakurai M, Zen Y, Nakanuma Y, Kaneko S. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007;132:282-93. [PMID: 17241878 DOI: 10.1053/j.gastro.2006.10.014] [Cited by in Crossref: 178] [Cited by in F6Publishing: 188] [Article Influence: 11.1] [Reference Citation Analysis]
539 Oral EA, Depaoli AM. Clinical Applications of Leptin. Leptin. [DOI: 10.1007/978-0-387-31416-7_17] [Reference Citation Analysis]
540 Kirsch R, Sijtsema HP, Tlali M, Marais AD, Hall Pde L. Effects of iron overload in a rat nutritional model of non-alcoholic fatty liver disease. Liver Int 2006;26:1258-67. [PMID: 17105592 DOI: 10.1111/j.1478-3231.2006.01329.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
541 Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82:315-22. [PMID: 16679470 DOI: 10.1136/pgmj.2005.042200] [Cited by in Crossref: 176] [Cited by in F6Publishing: 191] [Article Influence: 10.4] [Reference Citation Analysis]
542 Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, Melzer E, Orr A, Caspi A, Malnick S. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006;40:949-55. [PMID: 17063117 DOI: 10.1097/01.mcg.0000225668.53673.e6] [Cited by in Crossref: 108] [Cited by in F6Publishing: 115] [Article Influence: 6.4] [Reference Citation Analysis]
543 Volker D, Yunianingtias D. Nutraceutical and Functional Food Application to Nonalcoholic Steatohepatitis. Handbook of Nutraceuticals and Functional Foods, Second Edition 2006. [DOI: 10.1201/9781420006186.ch26] [Reference Citation Analysis]
544 Alberici LC, Oliveira HC, Patrício PR, Kowaltowski AJ, Vercesi AE. Hyperlipidemic mice present enhanced catabolism and higher mitochondrial ATP-sensitive K+ channel activity. Gastroenterology 2006;131:1228-34. [PMID: 17030192 DOI: 10.1053/j.gastro.2006.07.021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
545 Valenti L, Dongiovanni P, Piperno A, Fracanzani AL, Maggioni M, Rametta R, Loria P, Casiraghi MA, Suigo E, Ceriani R, Remondini E, Trombini P, Fargion S. Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology 2006;44:857-64. [PMID: 17006922 DOI: 10.1002/hep.21329] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 3.8] [Reference Citation Analysis]
546 Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006;26:856-63. [PMID: 16911469 DOI: 10.1111/j.1478-3231.2006.01311.x] [Cited by in Crossref: 187] [Cited by in F6Publishing: 166] [Article Influence: 11.0] [Reference Citation Analysis]
547 Su CC, Wang K, Hsia TL, Chen CS, Tung TH. Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. J Clin Gastroenterol 2006;40:551-4. [PMID: 16825939 DOI: 10.1097/00004836-200607000-00015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
548 Wendel AA, Belury MA. Effects of conjugated linoleic acid and troglitazone on lipid accumulation and composition in lean and Zucker diabetic fatty (fa/fa) rats. Lipids 2006;41:241-7. [PMID: 16711598 DOI: 10.1007/s11745-006-5093-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
549 Madan K, Batra Y, Gupta SD, Chander B, Rajan KDA, Tewatia MS, Panda SK, Acharya SK. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World J Gastroenterol 2006; 12(21): 3400-3405 [PMID: 16733858 DOI: 10.3748/wjg.v12.i21.3400] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 52] [Article Influence: 2.9] [Reference Citation Analysis]
550 Leclercq I, Sempoux C. Hépatopathie non alcoolique: de la stéatose à la cirrhose. Acta Endosc 2006;36:299-314. [DOI: 10.1007/bf03006037] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
551 Esteve-lafuente E, Ricart-engel W. Esteatosis hepática y resistencia a la insulina: ¿qué ocurre primero? Clínica e Investigación en Arteriosclerosis 2006;18:72-82. [DOI: 10.1016/s0214-9168(06)73708-1] [Reference Citation Analysis]
552 Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, Hirasawa T, Itoh Y, Okanoue T. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 2006;26:613-20. [PMID: 16762007 DOI: 10.1111/j.1478-3231.2006.01265.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 109] [Article Influence: 6.4] [Reference Citation Analysis]
553 Chien KL, Hsu HC, Chao CL, Lee BC, Chen MF, Lee YT. Interaction of obesity, metabolic syndrome and Framingham risk on steatohepatitis among healthy Taiwanese: population-based nested case-control study. Cardiovasc Diabetol 2006;5:12. [PMID: 16707022 DOI: 10.1186/1475-2840-5-12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
554 Papatheodoridis GV, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K, Manesis EK. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat 2006;13:303-10. [PMID: 16637860 DOI: 10.1111/j.1365-2893.2005.00677.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 4.6] [Reference Citation Analysis]
555 Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006;43:1145-51. [PMID: 16628637 DOI: 10.1002/hep.21171] [Cited by in Crossref: 167] [Cited by in F6Publishing: 147] [Article Influence: 9.8] [Reference Citation Analysis]
556 Klein S, Mittendorfer B, Eagon JC, Patterson B, Grant L, Feirt N, Seki E, Brenner D, Korenblat K, McCrea J. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006;130:1564-72. [PMID: 16697719 DOI: 10.1053/j.gastro.2006.01.042] [Cited by in Crossref: 218] [Cited by in F6Publishing: 229] [Article Influence: 12.8] [Reference Citation Analysis]
557 Ahmed MH. Rosuvastatin: a safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH). Scand J Gastroenterol 2006;41:631. [PMID: 16638709 DOI: 10.1080/00365520500320060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
558 Caldwell SH, Al-osaimi A, Chang C, Davis C, Hespenheide EE, Krugner-higby L, Hylton AI, Iezzoni JC, Le TH, Nakamoto RK, Redick J, Peterson T. Nonalcoholic Fatty Liver (NAFL): Overview. NASH and Nutritional Therapy. [DOI: 10.1007/4-431-27172-4_1] [Reference Citation Analysis]
559 Yoon EJ, Hu KQ. Hepatitis C virus (HCV) infection and hepatic steatosis. Int J Med Sci 2006;3:53-6. [PMID: 16614743 DOI: 10.7150/ijms.3.53] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 2.2] [Reference Citation Analysis]
560 Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006;43:682-9. [PMID: 16502396 DOI: 10.1002/hep.21103] [Cited by in Crossref: 360] [Cited by in F6Publishing: 314] [Article Influence: 21.2] [Reference Citation Analysis]
561 Oliveira CP, Simplicio FI, Lima VM, Yuahasi K, Lopasso FP, Alves VA, Abdalla DS, Carrilho FJ, Laurindo FR, Oliveira MG. Oral administration of S-nitroso-N-acetylcysteine prevents the onset of non alcoholic fatty liver disease in rats. World J Gastroenterol 2006; 12(12): 1905-1911 [PMID: 16609997 DOI: 10.3748/wjg.v12.i12.1905] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
562 Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1-16. [PMID: 16436109 DOI: 10.1111/j.0959-9673.2006.00465.x] [Cited by in Crossref: 520] [Cited by in F6Publishing: 548] [Article Influence: 30.6] [Reference Citation Analysis]
563 Thomas V, Harish K. Are we overestimating the risks of NASH? Gastroenterology 2006;130:1015-6; author reply 1016-7. [PMID: 16530550 DOI: 10.1053/j.gastro.2006.01.078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
564 Gill HK, Wu GY. Non-alcoholic fatty liver disease and the metabolic syndrome: Effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? World J Gastroenterol 2006; 12(3): 345-353 [PMID: 16489632 DOI: 10.3748/wjg.v12.i3.345] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
565 Metabolic disorders and storage diseases. Hepatology Principles and Practice. [DOI: 10.1007/3-540-28977-1_31] [Reference Citation Analysis]
566 Comar KM, Sterling RK. Review article: Drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006;23:207-15. [PMID: 16393299 DOI: 10.1111/j.1365-2036.2006.02751.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
567 Kim SY, Lee HJ, Park TS, Kim SG, Shin HJ. Adolescent obesity and the elevation of aminotransferase levels. Korean J Pediatr 2006;49:1037. [DOI: 10.3345/kjp.2006.49.10.1037] [Reference Citation Analysis]
568 Kim JM, Park JY, Nam HK, Kim JW, Park SK, Nam KJ, Park M, Lee H, Kim DK. Prevalence of Metabolic Syndrome in Type 2 DM Patients with Non-alcoholic Fatty Liver. J Korean Diabetes Assoc 2006;30:442. [DOI: 10.4093/jkda.2006.30.6.442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
569 Singh SP. Non-alcoholic fatty liver disease: the unfolding monster? J Gastroenterol Hepatol 2006;21:199-201. [PMID: 16460473 DOI: 10.1111/j.1440-1746.2006.04206.x] [Cited by in Crossref: 160] [Cited by in F6Publishing: 158] [Article Influence: 9.4] [Reference Citation Analysis]
570 Papanas N, Symeonidis G, Mavridis G, Papazoglou D, Giannakis I, Papatheodorou K, Pastore F, Lakasas G, Maltezos E. Severity of liver echogenicity is correlated to serum c-peptide levels in type 2 diabetic patients. Acta Clin Belg 2006;61:5-9. [PMID: 16673610 DOI: 10.1179/acb.2006.002] [Reference Citation Analysis]
571 Moon JH, Kim HJ, Kim SK, Shim WS, Kang ES, Rhee Y, Ahn CW, Lim SK, Kim KR, Lee HC, Cha BS. Long-term Effect of Pioglitazone Treatment in Patients with Type 2 Diabetes. J Korean Diabetes Assoc 2006;30:264. [DOI: 10.4093/jkda.2006.30.4.264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
572 Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. J Hum Nutr Diet 2005;18:365-70. [PMID: 16150132 DOI: 10.1111/j.1365-277X.2005.00634.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 3.4] [Reference Citation Analysis]
573 Martín-castillo A, García-pérez B, Ayala I, Adánez G, Ortega J, Sánchez M, Castells M. Evaluación macroscópica y microscópica del efecto de la atorvastatina sobre la progresión-regresión de la esteatosis hepática en un modelo aviar. Clínica e Investigación en Arteriosclerosis 2005;17:270-276. [DOI: 10.1016/s0214-9168(05)73354-4] [Reference Citation Analysis]
574 Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42:987-1000. [PMID: 16250043 DOI: 10.1002/hep.20920] [Cited by in Crossref: 564] [Cited by in F6Publishing: 529] [Article Influence: 31.3] [Reference Citation Analysis]
575 Cortez-Pinto H. Concluding remarks: metabolic syndrome, liver and HCV. Aliment Pharmacol Ther 2005;22 Suppl 2:83-5. [PMID: 16225481 DOI: 10.1111/j.1365-2036.2005.02604.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
576 Assy N, Bekirov I, Mejritsky Y, Solomon L, Szvalb S, Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 2005; 11(37): 5834-5839 [PMID: 16270394 DOI: 10.3748/wjg.v11.i37.5834] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 47] [Article Influence: 2.4] [Reference Citation Analysis]
577 Kim HC, Choi SH, Shin HW, Cheong JY, Lee KW, Lee HC, Huh KB, Kim DJ. Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. World J Gastroenterol 2005; 11(34): 5314-5321 [PMID: 16149138 DOI: 10.3748/wjg.v11.i34.5314] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 37] [Article Influence: 1.7] [Reference Citation Analysis]
578 Yoon D, Lee SH, Park HS, Lee JH, Park JS, Cho KH, Kim SM. Hypoadiponectinemia and insulin resistance are associated with nonalcoholic fatty liver disease. J Korean Med Sci. 2005;20:421-426. [PMID: 15953863 DOI: 10.3346/jkms.2005.20.3.421] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
579 Marchesini G, Avagnina S, Barantani EG, Ciccarone AM, Corica F, Dall'Aglio E, Dalle Grave R, Morpurgo PS, Tomasi F, Vitacolonna E. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest. 2005;28:333-339. [PMID: 15966506 DOI: 10.1007/bf03347199] [Cited by in Crossref: 107] [Cited by in F6Publishing: 110] [Article Influence: 5.9] [Reference Citation Analysis]
580 Sajjad A, Mottershead M, Syn WK, Jones R, Smith S, Nwokolo CU. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005;22:291-9. [PMID: 16097995 DOI: 10.1111/j.1365-2036.2005.02562.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 3.0] [Reference Citation Analysis]
581 Guidorizzi de Siqueira AC, Cotrim HP, Rocha R, Carvalho FM, de Freitas LA, Barreto D, Gouveia L, Landeiro L. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol 2005;17:837-41. [PMID: 16003133 DOI: 10.1097/00042737-200508000-00010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
582 Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343-1351. [PMID: 15864352 DOI: 10.1172/jci200523621] [Cited by in Crossref: 130] [Cited by in F6Publishing: 102] [Article Influence: 7.2] [Reference Citation Analysis]
583 Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343-1351. [PMID: 15864352 DOI: 10.1172/jci23621] [Cited by in Crossref: 2112] [Cited by in F6Publishing: 2285] [Article Influence: 117.3] [Reference Citation Analysis]
584 Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52. [PMID: 15895401 DOI: 10.1002/hep.20734] [Cited by in Crossref: 877] [Cited by in F6Publishing: 830] [Article Influence: 48.7] [Reference Citation Analysis]
585 Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J Pediatr Gastroenterol Nutr 2005;41:94-8. [PMID: 15990637 DOI: 10.1097/01.mpg.0000164698.03164.e5] [Cited by in Crossref: 102] [Cited by in F6Publishing: 108] [Article Influence: 5.7] [Reference Citation Analysis]
586 Solis-Herruzo JA, Pérez-Carreras M, Rivas E, Fernández-Vázquez I, Garfia C, Bernardos E, Castellano G, Colina F. Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 2005;100:1091-8. [PMID: 15842583 DOI: 10.1111/j.1572-0241.2005.41059.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
587 Uraz S, Aygun C, Sonsuz A, Ozbay G. Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis. Dig Dis Sci 2005;50:964-9. [PMID: 15906776 DOI: 10.1007/s10620-005-2672-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
588 Völzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Lüdemann J, Schminke U, Kessler C, John U. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005; 11(12): 1848-1853 [PMID: 15793879 DOI: 10.3748/wjg.v11.i12.1848] [Cited by in CrossRef: 172] [Cited by in F6Publishing: 188] [Article Influence: 9.6] [Reference Citation Analysis]
589 Dong H, Lu FE, Gao ZQ, Xu LJ, Wang KF, Zou X. Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw. World J Gastroenterol 2005; 11(9): 1339-1344 [PMID: 15761972 DOI: 10.3748/wjg.v11.i9.1339] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
590 Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634-42. [PMID: 15747110 DOI: 10.1007/s00125-005-1682-x] [Cited by in Crossref: 478] [Cited by in F6Publishing: 432] [Article Influence: 26.6] [Reference Citation Analysis]
591 Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 2005;128:627-35. [PMID: 15810122 DOI: 10.1053/j.gastro.2004.12.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 3.3] [Reference Citation Analysis]
592 Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol 2005;39:237-42. [PMID: 15718867 DOI: 10.1097/01.mcg.0000152747.79773.2f] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 3.8] [Reference Citation Analysis]
593 Wang M. The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. Nutr Metab (Lond). 2005;2:3. [PMID: 15689240 DOI: 10.1186/1743-7075-2-3] [Cited by in Crossref: 182] [Cited by in F6Publishing: 197] [Article Influence: 10.1] [Reference Citation Analysis]
594 Angelico F, Alessandri C, Burattin M, Del Ben M, Orando S, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. The Cochrane Database of Systematic Reviews 2005. [DOI: 10.1002/14651858.cd005166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
595 Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, Lindor K. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005;41:64-71. [PMID: 15690483 DOI: 10.1002/hep.20543] [Cited by in Crossref: 141] [Cited by in F6Publishing: 133] [Article Influence: 7.8] [Reference Citation Analysis]
596 Kagansky N, Levy S, Keter D, Rimon E, Taiba Z, Fridman Z, Berger D, Knobler H, Malnick S. Non-alcoholic fatty liver disease--a common and benign finding in octogenarian patients. Liver Int 2004;24:588-94. [PMID: 15566509 DOI: 10.1111/j.1478-3231.2004.0969.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 2.9] [Reference Citation Analysis]
597 Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-15. [PMID: 15625656 DOI: 10.1016/s1542-3565(04)00457-4] [Cited by in Crossref: 318] [Cited by in F6Publishing: 319] [Article Influence: 16.7] [Reference Citation Analysis]
598 Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365-8. [PMID: 15571584 DOI: 10.1111/j.1572-0241.2004.40064.x] [Cited by in Crossref: 175] [Cited by in F6Publishing: 171] [Article Influence: 9.2] [Reference Citation Analysis]
599 Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95. [PMID: 15565570 DOI: 10.1002/hep.20466] [Cited by in Crossref: 2611] [Cited by in F6Publishing: 2469] [Article Influence: 137.4] [Reference Citation Analysis]
600 Gawrieh S, Opara EC, Koch TR. Oxidative Stress in Nonalcoholic Fatty Liver Disease: Pathogenesis and Antioxidant Therapies. Journal of Investigative Medicine 2004;52:506-514. [DOI: 10.1177/108155890405200822] [Reference Citation Analysis]
601 Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004;16:1087-93. [PMID: 15489565 DOI: 10.1097/00042737-200411000-00002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 4.3] [Reference Citation Analysis]
602 Zhang GY, Nie L. Leptin and estrogen in pathogenesis of nonalcoholic fatty liver disease in male adults. Shijie Huaren Xiaohua Zazhi 2004; 12(8): 1897-1899 [DOI: 10.11569/wcjd.v12.i8.1897] [Reference Citation Analysis]
603 Yajima K, Shimada A, Hirose H, Kasuga A, Saruta T. "Low dose" metformin improves hyperglycemia better than acarbose in type 2 diabetics. Rev Diabet Stud 2004;1:89-94. [PMID: 17491670 DOI: 10.1900/RDS.2004.1.89] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
604 Contos MJ, Choudhury J, Mills AS, Sanyal AJ. The histologic spectrum of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:481-500, vii. [PMID: 15331059 DOI: 10.1016/j.cld.2004.04.013] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
605 Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004;8:501-19, vii. [PMID: 15331060 DOI: 10.1016/j.cld.2004.04.008] [Cited by in Crossref: 126] [Cited by in F6Publishing: 128] [Article Influence: 6.6] [Reference Citation Analysis]
606 Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:575-94, ix. [PMID: 15331065 DOI: 10.1016/j.cld.2004.04.006] [Cited by in Crossref: 108] [Cited by in F6Publishing: 110] [Article Influence: 5.7] [Reference Citation Analysis]
607 Sánchez-Muñoz D, Romero-Gómez M, González-Escribano MF, Torres B, Castellano-Megias VM, Gómez-Izquierdo L, Aguilar-Reina J, Nuñez-Roldan A. Tumour necrosis factor alpha polymorphisms are not involved in the development of steatosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2004;16:761-5. [PMID: 15256977 DOI: 10.1097/01.meg.0000108368.19243.97] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
608 Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:1497-502. [PMID: 15307867 DOI: 10.1111/j.1572-0241.2004.30159.x] [Cited by in Crossref: 252] [Cited by in F6Publishing: 244] [Article Influence: 13.3] [Reference Citation Analysis]
609 Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004;20:23-8. [PMID: 15225167 DOI: 10.1111/j.1365-2036.2004.02025.x] [Cited by in Crossref: 263] [Cited by in F6Publishing: 239] [Article Influence: 13.8] [Reference Citation Analysis]
610 Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004;53:1020-3. [PMID: 15194655 DOI: 10.1136/gut.2003.027086] [Cited by in Crossref: 160] [Cited by in F6Publishing: 153] [Article Influence: 8.4] [Reference Citation Analysis]
611 Wong VW, Chan HL, Hui AY, Chan KF, Liew CT, Chan FK, Sung JJ. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther 2004;20:45-9. [PMID: 15225170 DOI: 10.1111/j.1365-2036.2004.02012.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
612 Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004;40:185-94. [PMID: 15239102 DOI: 10.1002/hep.20283] [Cited by in Crossref: 581] [Cited by in F6Publishing: 572] [Article Influence: 30.6] [Reference Citation Analysis]
613 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(6): 1485-1487 [DOI: 10.11569/wcjd.v12.i6.1485] [Reference Citation Analysis]
614 Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, Sung IK, Park CY, Sohn CI, Jeon WK, Kim H, Rhee EJ, Lee WY, Kim SW. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004;19:694-8. [PMID: 15151626 DOI: 10.1111/j.1440-1746.2004.03362.x] [Cited by in Crossref: 141] [Cited by in F6Publishing: 136] [Article Influence: 7.4] [Reference Citation Analysis]
615 Magalotti D, Marchesini G, Ramilli S, Berzigotti A, Bianchi G, Zoli M. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig Liver Dis 2004;36:406-11. [PMID: 15248381 DOI: 10.1016/j.dld.2004.01.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
616 Elefsiniotis IS, Pantazis KD, Ilias A, Pallis L, Mariolis A, Glynou I, Kada H, Moulakakis A. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. Eur J Gastroenterol Hepatol 2004;16:593-8. [PMID: 15167162 DOI: 10.1097/00042737-200406000-00013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
617 Marra F. NASH: are genes blowing the hits? J Hepatol 2004;40:853-6. [PMID: 15094235 DOI: 10.1016/j.jhep.2004.03.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
618 Bardella MT, Valenti L, Pagliari C, Peracchi M, Farè M, Fracanzani AL, Fargion S. Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Dig Liver Dis 2004;36:333-6. [PMID: 15191202 DOI: 10.1016/j.dld.2004.01.012] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 3.3] [Reference Citation Analysis]
619 Chen QK, Chen HY, Wang LY, Chen WX, Huang ZQ. Association between fatty liver and hyperlipidemia. Shijie Huaren Xiaohua Zazhi 2004; 12(4): 914-916 [DOI: 10.11569/wcjd.v12.i4.914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
620 Caballera J. Esteatohepatitis no alcoh?lica. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2004;9:459-465. [DOI: 10.1016/s0211-3449(04)70058-2] [Reference Citation Analysis]
621 Chen QK, Chen HY, Huang KH, Zhong YQ, Han JA, Zhu ZH, Zhou XD. Clinical features and risk factors of patients with fatty liver in Guangzhou area. World J Gastroenterol 2004; 10(6): 899-902 [PMID: 15040041 DOI: 10.3748/wjg.v10.i6.899] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
622 Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 2004;36:165-73. [PMID: 15046183 DOI: 10.1016/j.dld.2003.12.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 3.4] [Reference Citation Analysis]
623 Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44. [PMID: 14987322 DOI: 10.1111/j.1365-2036.2004.01888.x] [Cited by in Crossref: 293] [Cited by in F6Publishing: 272] [Article Influence: 15.4] [Reference Citation Analysis]
624 Chin K. Effects of therapy on the metabolism and humoral factors in patients with obstructive sleep apnea-hypopnea syndrome. Sleep and Biological Rhythms 2004;2:23-27. [DOI: 10.1111/j.1479-8425.2003.00080.x] [Reference Citation Analysis]
625 Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004;99:292-8. [PMID: 15046220 DOI: 10.1111/j.1572-0241.2004.04059.x] [Cited by in Crossref: 161] [Cited by in F6Publishing: 154] [Article Influence: 8.5] [Reference Citation Analysis]
626 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8. [PMID: 14762783 DOI: 10.1053/j.gastro.2003.10.065] [Cited by in Crossref: 862] [Cited by in F6Publishing: 904] [Article Influence: 45.4] [Reference Citation Analysis]
627 Conjeevaram HS. Gender-Specific Issues in Liver Diseases. Principles of Gender-Specific Medicine 2004. [DOI: 10.1016/b978-012440905-7/50312-1] [Reference Citation Analysis]
628 Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:179-87. [PMID: 14752836 DOI: 10.1002/hep.20023] [Cited by in Crossref: 301] [Cited by in F6Publishing: 277] [Article Influence: 15.8] [Reference Citation Analysis]
629 Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, Considine RV. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 2003;98:2771-6. [PMID: 14687831 DOI: 10.1111/j.1572-0241.2003.08767.x] [Cited by in Crossref: 104] [Cited by in F6Publishing: 102] [Article Influence: 5.2] [Reference Citation Analysis]
630 Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, Jonsson JR. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003;39:1042-8. [PMID: 14642624 DOI: 10.1016/s0168-8278(03)00463-x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 132] [Article Influence: 6.4] [Reference Citation Analysis]
631 Nightingale JM. Hepatobiliary, renal and bone complications of intestinal failure. Best Pract Res Clin Gastroenterol 2003;17:907-29. [PMID: 14642857 DOI: 10.1016/s1521-6918(03)00108-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 3.4] [Reference Citation Analysis]
632 Kaukiainen A, Vehmas T, Rantala K, Nurminen M, Martikainen R, Taskinen H. Results of common laboratory tests in solvent-exposed workers. Int Arch Occup Environ Health 2004;77:39-46. [PMID: 14600835 DOI: 10.1007/s00420-003-0476-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
633 Sargin M, Uygur-Bayramiçli O, Sargin H, Orbay E, Yayla A. Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease? J Clin Gastroenterol 2003;37:399-402. [PMID: 14564188 DOI: 10.1097/00004836-200311000-00010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
634 Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol 2003;37:340-3. [PMID: 14506393 DOI: 10.1097/00004836-200310000-00014] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 5.5] [Reference Citation Analysis]
635 Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 2003;125:1053-9. [PMID: 14517789 DOI: 10.1016/s0016-5085(03)01200-9] [Cited by in Crossref: 88] [Cited by in F6Publishing: 91] [Article Influence: 4.4] [Reference Citation Analysis]
636 Hookman P, Barkin JS. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach. Am J Gastroenterol 2003;98:2093-7. [PMID: 14499793 DOI: 10.1111/j.1572-0241.2003.07670.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
637 Achten J, Sutedja D, Johnson J, Jeukendrup A, Jones D, Elias E. Treatment of Nonalcoholic Steatohepatitis: The Effects of Regular Exercise. European Journal of Sport Science 2003;3:1-13. [DOI: 10.1080/17461390300073404] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
638 Chalasani N, Deeg MA, Persohn S, Crabb DW. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:1849-55. [PMID: 12907343 DOI: 10.1111/j.1572-0241.2003.07619.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
639 Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003;38:244-51. [PMID: 12830008 DOI: 10.1053/jhep.2003.50290] [Cited by in Crossref: 132] [Cited by in F6Publishing: 119] [Article Influence: 6.6] [Reference Citation Analysis]
640 Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, Li JQ, Chen SY. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003; 9(5): 1106-1110 [PMID: 12717867 DOI: 10.3748/wjg.v9.i5.1106] [Cited by in CrossRef: 127] [Cited by in F6Publishing: 129] [Article Influence: 6.4] [Reference Citation Analysis]
641 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19. [PMID: 12717402 DOI: 10.1053/jhep.2003.50193] [Cited by in Crossref: 1471] [Cited by in F6Publishing: 1362] [Article Influence: 73.6] [Reference Citation Analysis]
642 Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, Antonini TM, Alessandri C. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 2003;18:588-94. [PMID: 12702052 DOI: 10.1046/j.1440-1746.2003.02958.x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 124] [Article Influence: 6.3] [Reference Citation Analysis]
643 Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003;38:681-7. [PMID: 12713883 DOI: 10.1016/s0168-8278(03)00097-7] [Cited by in Crossref: 131] [Cited by in F6Publishing: 142] [Article Influence: 6.6] [Reference Citation Analysis]
644 Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7. [PMID: 12809815 DOI: 10.1111/j.1572-0241.2003.07486.x] [Cited by in Crossref: 930] [Cited by in F6Publishing: 933] [Article Influence: 46.5] [Reference Citation Analysis]
645 Yu AS, Keeffe EB. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence? Am J Gastroenterol 2003;98:955-6. [PMID: 12809814 DOI: 10.1111/j.1572-0241.2003.07485.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 3.0] [Reference Citation Analysis]
646 Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep. 2002;2:210-215. [PMID: 12643175 DOI: 10.1007/s11892-002-0085-3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 3.9] [Reference Citation Analysis]
647 Merat S, Malekzadeh R, Sohrabi MR, Sotoudeh M, Rakhshani N, Sohrabpour AA, Naserimoghadam S. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003;38:414-8. [PMID: 12663231 DOI: 10.1016/s0168-8278(02)00441-5] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 4.4] [Reference Citation Analysis]
648 Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003;98:926-30. [PMID: 12738478 DOI: 10.1111/j.1572-0241.2003.07375.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
649 Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23. [PMID: 12668987 DOI: 10.1053/jhep.2003.50161] [Cited by in Crossref: 1891] [Cited by in F6Publishing: 1722] [Article Influence: 94.6] [Reference Citation Analysis]
650 Sørensen HT, Mellemkjaer L, Jepsen P, Thulstrup AM, Baron J, Olsen JH, Vilstrup H. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol 2003;36:356-9. [PMID: 12642745 DOI: 10.1097/00004836-200304000-00015] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 3.9] [Reference Citation Analysis]
651 Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003;38:434-40. [PMID: 12663234 DOI: 10.1016/s0168-8278(03)00027-8] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 4.6] [Reference Citation Analysis]
652 Alba LM, Lindor K. Review article: Non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003;17:977-86. [PMID: 12694079 DOI: 10.1046/j.1365-2036.2003.01493.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 3.8] [Reference Citation Analysis]
653 Kaido T, Honda Y, Kitamura K. Association between Liver Dysfunction and Hyperglycemia in Japanese Male Workers at Printing and Papermaking Plants. Jrnl of Occup Health 2003;44:301-6. [DOI: 10.1539/joh.44.301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
654 Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003;37:544-50. [PMID: 12601351 DOI: 10.1053/jhep.2003.50095] [Cited by in Crossref: 232] [Cited by in F6Publishing: 222] [Article Influence: 11.6] [Reference Citation Analysis]
655 Jeurissen A, Boudewijns M, Proesmans M, Ceuppens JL, De Boeck K, Bossuyt X. Evaluation of the immune response to pneumococcal capsular polysaccharides. Acta Clin Belg 2003;58:106-10. [PMID: 12836493 DOI: 10.1179/acb.2003.58.2.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
656 Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, Bertelli C, Taioli E, Fiorelli G, Fargion S. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003;35:172-8. [PMID: 12779071 DOI: 10.1016/s1590-8658(03)00025-2] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 3.3] [Reference Citation Analysis]
657 Merat S, Malekzadeh R, Sohrabi MR, Hormazdi M, Naserimoghadam S, Mikaeli J, Farahvash MJ, Ansari R, Sotoudehmanesh R, Khatibian M. Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study. J Clin Gastroenterol 2003;36:266-8. [PMID: 12590240 DOI: 10.1097/00004836-200303000-00015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
658 Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-50. [PMID: 12540784 DOI: 10.1053/jhep.2003.50048] [Cited by in Crossref: 653] [Cited by in F6Publishing: 637] [Article Influence: 32.7] [Reference Citation Analysis]
659 Hookman P, Barkin JS. Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach. Am J Gastroenterol 2003;98:495-9. [PMID: 12591075 DOI: 10.1111/j.1572-0241.2003.07276.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
660 Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol 2003;18:124-38. [PMID: 12542595 DOI: 10.1046/j.1440-1746.2003.02989.x] [Cited by in Crossref: 172] [Cited by in F6Publishing: 156] [Article Influence: 8.6] [Reference Citation Analysis]
661 Harrison SA, Di Bisceglie AM. Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease: . Drugs 2003;63:2379-94. [DOI: 10.2165/00003495-200363220-00001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 2.1] [Reference Citation Analysis]
662 Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003;5:18-25. [DOI: 10.1007/s11894-003-0005-y] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 3.1] [Reference Citation Analysis]
663 Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-9. [PMID: 12512031 DOI: 10.1053/gast.2003.50004] [Cited by in Crossref: 417] [Cited by in F6Publishing: 434] [Article Influence: 20.9] [Reference Citation Analysis]
664 Miyake Y, Eguchi H, Shinchi K, Oda T, Sasazuki S, Kono S. Glucose intolerance and serum aminotransferase activities in Japanese men. J Hepatol 2003;38:18-23. [PMID: 12480555 DOI: 10.1016/s0168-8278(02)00323-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
665 Sanyal AJ; American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25. [PMID: 12404245 DOI: 10.1053/gast.2002.36572] [Cited by in Crossref: 752] [Cited by in F6Publishing: 799] [Article Influence: 35.8] [Reference Citation Analysis]
666 Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002;97:2714-24. [PMID: 12425538 DOI: 10.1111/j.1572-0241.2002.07069.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 43] [Article Influence: 0.5] [Reference Citation Analysis]
667 Iglesias MA, Ye JM, Frangioudakis G, Saha AK, Tomas E, Ruderman NB, Cooney GJ, Kraegen EW. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002;51:2886-94. [PMID: 12351423 DOI: 10.2337/diabetes.51.10.2886] [Cited by in Crossref: 221] [Cited by in F6Publishing: 230] [Article Influence: 10.5] [Reference Citation Analysis]
668 Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol 2002;16:733-47. [PMID: 12406442 DOI: 10.1053/bega.2002.0334] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 2.6] [Reference Citation Analysis]
669 Koteish A, Mae Diehl A. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:679-90. [PMID: 12406439 DOI: 10.1053/bega.2002.0332] [Cited by in Crossref: 125] [Cited by in F6Publishing: 128] [Article Influence: 6.0] [Reference Citation Analysis]
670 Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50. [PMID: 12198701 DOI: 10.1053/gast.2002.35354] [Cited by in Crossref: 1347] [Cited by in F6Publishing: 1419] [Article Influence: 64.1] [Reference Citation Analysis]
671 Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002;123:882-932. [PMID: 12198715 DOI: 10.1053/gast.2002.35514] [Cited by in Crossref: 183] [Cited by in F6Publishing: 189] [Article Influence: 8.7] [Reference Citation Analysis]
672 Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, Liddle C, Samarasinghe D, George J. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002;36:403-9. [PMID: 12143049 DOI: 10.1053/jhep.2002.34738] [Cited by in Crossref: 244] [Cited by in F6Publishing: 225] [Article Influence: 11.6] [Reference Citation Analysis]
673 Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology 2002;123:375-8. [PMID: 12105866 DOI: 10.1053/gast.2002.34453] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
674 Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40. [PMID: 12105842 DOI: 10.1053/gast.2002.34168] [Cited by in Crossref: 1035] [Cited by in F6Publishing: 1113] [Article Influence: 49.3] [Reference Citation Analysis]
675 El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002;122:1822-8. [PMID: 12055590 DOI: 10.1053/gast.2002.33650] [Cited by in Crossref: 116] [Cited by in F6Publishing: 121] [Article Influence: 5.5] [Reference Citation Analysis]
676 Cassader M, Gambino R, Musso G, Depetris N, Mecca F, Cavallo-Perin P, Pacini G, Rizzetto M, Pagano G. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids. 2001;36:1117-1124. [PMID: 11768156 DOI: 10.1007/s11745-001-0822-5] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 3.2] [Reference Citation Analysis]
677 Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57. [PMID: 12016429 DOI: 10.1053/gast.2002.33573] [Cited by in Crossref: 636] [Cited by in F6Publishing: 662] [Article Influence: 30.3] [Reference Citation Analysis]
678 Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002;122:931-9. [PMID: 11910345 DOI: 10.1053/gast.2002.32403] [Cited by in Crossref: 176] [Cited by in F6Publishing: 178] [Article Influence: 8.4] [Reference Citation Analysis]
679 Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35:746-52. [PMID: 11915019 DOI: 10.1053/jhep.2002.32483] [Cited by in Crossref: 178] [Cited by in F6Publishing: 143] [Article Influence: 8.5] [Reference Citation Analysis]
680 McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002;34:255-62. [PMID: 11873108 DOI: 10.1097/00004836-200203000-00013] [Cited by in Crossref: 226] [Cited by in F6Publishing: 221] [Article Influence: 10.8] [Reference Citation Analysis]
681 Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone AM, Bagni A, Bertolotti M, Ganazzi D, Carulli N; POLI.ST.E.N.A. Study Group. Policentrica Steatosi Epatica Non Alcolica. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis 2002;34:204-11. [PMID: 11990393 DOI: 10.1016/s1590-8658(02)80194-3] [Cited by in Crossref: 89] [Cited by in F6Publishing: 91] [Article Influence: 4.2] [Reference Citation Analysis]
682 Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002;35:497-9. [PMID: 11826428 DOI: 10.1053/jhep.2002.31551] [Cited by in Crossref: 95] [Cited by in F6Publishing: 85] [Article Influence: 4.5] [Reference Citation Analysis]
683 Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-9. [PMID: 11826411 DOI: 10.1053/jhep.2002.30692] [Cited by in Crossref: 799] [Cited by in F6Publishing: 707] [Article Influence: 38.0] [Reference Citation Analysis]
684 Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002;122:274-80. [PMID: 11832442 DOI: 10.1053/gast.2002.31065] [Cited by in Crossref: 221] [Cited by in F6Publishing: 231] [Article Influence: 10.5] [Reference Citation Analysis]
685 Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002;17 Suppl:S186-90. [PMID: 12000605 DOI: 10.1046/j.1440-1746.17.s1.10.x] [Cited by in Crossref: 308] [Cited by in F6Publishing: 295] [Article Influence: 14.7] [Reference Citation Analysis]
686 Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002;282:G1-5. [PMID: 11751151 DOI: 10.1152/ajpgi.00384.2001] [Cited by in Crossref: 117] [Cited by in F6Publishing: 118] [Article Influence: 5.6] [Reference Citation Analysis]
687 Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol 2002;9:37-51. [PMID: 11756758 DOI: 10.1097/00125480-200201000-00005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 2.2] [Reference Citation Analysis]
688 Susca M, Grassi A, Zauli D, Volta U, Lenzi M, Marchesini G, Bianchi FB, Ballardini G. Liver inflammatory cells, apoptosis, regeneration and stellate cell activation in non-alcoholic steatohepatitis. Dig Liver Dis 2001;33:768-77. [PMID: 11838612 DOI: 10.1016/s1590-8658(01)80694-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
689 Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-61. [PMID: 11693332 DOI: 10.1111/j.1572-0241.2001.04667.x] [Cited by in Crossref: 272] [Cited by in F6Publishing: 275] [Article Influence: 12.4] [Reference Citation Analysis]
690 Neuschwander-Tetri BA. A resistance movement in NASH. Am J Gastroenterol 2001;96:2813-4. [PMID: 11693313 DOI: 10.1111/j.1572-0241.2001.04571.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
691 Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121:710-23. [PMID: 11522755 DOI: 10.1053/gast.2001.27126] [Cited by in Crossref: 352] [Cited by in F6Publishing: 373] [Article Influence: 16.0] [Reference Citation Analysis]
692 Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92. [PMID: 11266382 DOI: 10.1053/gast.2001.23256] [Cited by in Crossref: 1441] [Cited by in F6Publishing: 1504] [Article Influence: 65.5] [Reference Citation Analysis]
693 Angulo P, Lindor KD. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001;120:1281-5. [PMID: 11266392 DOI: 10.1053/gast.2001.23591] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 2.0] [Reference Citation Analysis]
694 Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-73. [PMID: 11303298 DOI: 10.1053/jlts.2001.23011] [Cited by in Crossref: 296] [Cited by in F6Publishing: 273] [Article Influence: 13.5] [Reference Citation Analysis]
695 Sanyal AJ. Insulin resistance and nonalcoholic steatohepatitis: fat or fiction? Am J Gastroenterol 2001;96:274-6. [PMID: 11232664 DOI: 10.1111/j.1572-0241.2001.03548.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
696 Lonardo A, Loria P, Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI.ST.E.N.A. study. Dig Liver Dis 2001;33:86-7. [PMID: 11303985 DOI: 10.1016/s1590-8658(01)80144-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
697 Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000;119:1340-7. [PMID: 11054393 DOI: 10.1053/gast.2000.19267] [Cited by in Crossref: 245] [Cited by in F6Publishing: 257] [Article Influence: 10.7] [Reference Citation Analysis]
698 Tarugi P, Lonardo A, Ballarini G, Erspamer L, Tondelli E, Bertolini S, Calandra S. A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). J Hepatol 2000;33:361-70. [PMID: 11019990 DOI: 10.1016/s0168-8278(00)80270-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 1.8] [Reference Citation Analysis]